Thrombotic Thrombocytopenia after ChAdOx1 nCov-19

New England Journal of Medicine 384, 2092-2101 DOI: 10.1056/nejmoa2104840

Citation Report

#	Article	IF	CITATIONS
1	Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea. Journal of Korean Medical Science, 2021, 36, e223.	1.1	19
2	Risks of Emergency Department Visits, Hospitalisations, Life-Threatening Events, and Deaths After SARS/nCoV2 Vaccination in the US: An Observational Study Using National Data. SSRN Electronic Journal, 0, , .	0.4	0
3	Acute myocarditis following administration of BNT162b2 vaccine. IDCases, 2021, 25, e01197.	0.4	33
4	Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. Journal of Korean Medical Science, 2021, 36, e232.	1.1	16
5	Safety of COVID-19 vaccines administered in the EU: Should we be concerned?. Toxicology Reports, 2021, 8, 871-879.	1.6	95
6	Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation. Saudi Journal of Gastroenterology, 2021, 27, 201.	0.5	5
7	Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine. Journal of Korean Medical Science, 2021, 36, e197.	1.1	18
8	Orofacial adverse effects of COVID-19 vaccines exist but are rare. Evidence-Based Dentistry, 2021, 22, 70-71.	0.3	3
9	The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines. Immunotherapy Advances, 2021, 1, ltab019.	1.2	4
10	Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects. Oncotarget, 2021, 12, 2476-2488.	0.8	7
11	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110214.	0.7	29
12	Side effects following COVID-19 vaccination: A cross-sectional survey with age-related outcomes in Saudi Arabia. Journal of Advanced Pharmacy Education and Research, 2021, 11, 119-125.	0.2	10
13	Coronavirus disease 2019 vaccines and relevant adverse reactions. Allergy Asthma & Respiratory Disease, 2021, 9, 124.	0.3	3
14	Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110401.	0.7	6
16	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations. Journal of the Canadian Association of Gastroenterology, 2021, 4, S54-S60.	0.1	9
17	Assessing Case Fatality and the Effect of Treatment on Cases of Thrombosis With Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca in the United Kingdom. SSRN Electronic Journal, 0, , .	0.4	0
18	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3
19	Reactogenicity and Immunogenicity of Heterologous ChAdOx1-nCoV19 and BNT162b2 Vaccination: A Systematic Review and Meta-Analysis of the Heterologous COVID-19 Vaccination Outcomes. SSRN Electronic Journal, 0, , .	0.4	1

#	Article	IF	CITATIONS
20	Spotlight on Adenovirus-Based Vaccines and Rare Thrombotic Events. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110208.	0.7	3
22	No country or continent is on its own in the ongoing COVID-19 pandemic. Eurosurveillance, 2021, 26, .	3.9	4
23	PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021032.	0.5	17
24	Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. European Respiratory Journal, 2021, 58, 2100956.	3.1	115
25	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals, 2021, 14, 406.	1.7	101
26	Thrombosis after covid-19 vaccination. BMJ, The, 2021, 373, n958.	3.0	87
28	Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 651-656.	9.0	158
30	Covid-19: Rare immune response may cause clots after AstraZeneca vaccine, say researchers. BMJ, The, 2021, 373, n954.	3.0	20
31	The association of thrombosis with thrombocytopenia syndrome with cerebral venous thrombosis. American Journal of Emergency Medicine, 2022, 53, 269-270.	0.7	1
32	Lessons from the United Kingdom's COVIDâ€19 vaccination strategy. Medical Journal of Australia, 2021, 214, 417-419.	0.8	6
33	Left inferior ophthalmic vein thrombosis due to VITT: a case report. QJM - Monthly Journal of the Association of Physicians, 2021, , .	0.2	10
34	ChAdOx1 S (recombinant) vaccine: thrombosis and thrombocytopenia. Drug and Therapeutics Bulletin, 2021, 59, 101-101.	0.3	1
35	Heparin-induced thrombocytopenia. Cmaj, 2021, 193, E736-E736.	0.9	29
36	Covid-19: Vaccine woes highlight vital role of traditional public health. BMJ, The, O, , n968.	3.0	1
37	Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). Medical Science Monitor, 2021, 27, e932899.	0.5	18
40	COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review of the potential mechanisms and proposed management. Science Progress, 2021, 104, 003685042110259.	1.0	22
41	The Hong Kong Society of Rheumatology Consensus Recommendations for COVID-19 Vaccination in Adult Patients with Autoimmune Rheumatic Diseases. Journal of Clinical Rheumatology and Immunology, 2021, 21, 7-14.	0.4	4
42	Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us – and what they don't. European Respiratory Journal, 2021, 58, 2101111.	3.1	20

#	Article	IF	CITATIONS
44	COVID vaccines and blood clots: five key questions. Nature, 2021, 592, 495-496.	13.7	42
47	Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 680-684.	9.0	152
48	How could a COVID vaccine cause blood clots? Scientists race to investigate. Nature, 2021, 592, 334-335.	13.7	21
49	Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood, 2021, 138, 350-353.	0.6	145
50	Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e77-e78.	1.4	10
52	Extending the clinical spectrum of thrombotic thrombocytopenic syndrome attributable to adenovirus-based vaccines for Covid-19. American Journal of Emergency Medicine, 2021, 54, 318-318.	0.7	0
54	Vaccine-related ophthalmic vein thrombosis in the wider context of VITT. QJM - Monthly Journal of the Association of Physicians, 2021, , .	0.2	1
55	Comparisons of Motivation to Receive COVID-19 Vaccination and Related Factors between Frontline Physicians and Nurses and the Public in Taiwan: Applying the Extended Protection Motivation Theory. Vaccines, 2021, 9, 528.	2.1	19
57	Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. Pathogens, 2021, 10, 636.	1.2	2
58	Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology, 2021, 268, 4483-4485.	1.8	37
62	PotentialÂadverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech). Journal of Pharmaceutical Policy and Practice, 2021, 14, 46.	1.1	14
63	Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. New England Journal of Medicine, 2021, 384, 1964-1965.	13.9	356
64	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood, 2021, 138, 299-303.	0.6	125
66	A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood, 2021, 137, 3656-3659.	0.6	52
67	Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism. Vaccines, 2021, 9, 559.	2.1	64
68	Thromboembolic Complications of SARS-CoV-2 and Metabolic Derangements: Suggestions from Clinical Practice Evidence to Causative Agents. Metabolites, 2021, 11, 341.	1.3	10
69	Ethnic and minority group differences in engagement with COVID-19 vaccination programmes – at Pandemic Pace; when vaccine confidence in mass rollout meets local vaccine hesitancy. Israel Journal of Health Policy Research, 2021, 10, 33.	1.4	26
70	Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity. PLoS Medicine, 2021, 18, e1003648.	3.9	39

#	Article	IF	CITATIONS
71	Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica, 2021, 106, 2170-2179.	1.7	101
72	Postâ€adenoviralâ€based COVIDâ€19 vaccines thrombosis: A proposed mechanism. Journal of Thrombosis and Haemostasis, 2021, 19, 1831-1832.	1.9	20
74	Recognizing, managing and reporting vaccine-induced immune thrombotic thrombocytopenia. Cmaj, 2021, 193, E913-E915.	0.9	10
75	Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination. NeurologÃa (English Edition), 2021, 36, 451-461.	0.2	10
76	Fatal Case of Acute Pulmonary Embolism due to Venous Thrombosis after COVID-19 Vaccination: Based on Forensic Postmortem Examination. Korean Journal of Legal Medicine, 2021, 45, 63-68.	0.1	0
77	Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica, 2021, 106, 2291-2293.	1.7	47
78	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thrombosis and Haemostasis, 2021, 121, 982-991.	1.8	50
80	PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia. New England Journal of Medicine, 2021, 385, 376-378.	13.9	91
81	Acute Macular Neuroretinopathy following Coronavirus Disease 2019 Vaccination. Ocular Immunology and Inflammation, 2021, 29, 730-733.	1.0	57
82	Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVIDâ€19 vaccine: another piece of SARSâ€CoVâ€2 skin puzzle?. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e543-e545.	1.3	30
83	Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1247-1248.	0.9	63
85	A new enemy is emerging in the fight against the SARS-CoV-2 pandemic. Haematologica, 2021, 106, 2040-2041.	1.7	7
86	Lessons learnt from COVIDâ€19 coagulopathy. EJHaem, 2021, 2, 577-584.	0.4	12
87	Limb ischemia and pulmonary artery thrombosis after the ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia. Cmaj, 2021, 193, E906-E910.	0.9	20
88	Thrombotic thrombocytopenia due to SARS-CoV-2 vaccination. Cleveland Clinic Journal of Medicine, 2021, , .	0.6	17
90	Vacunas COVID-19 e infección por herpes. Medicina ClÃnica, 2021, 157, e355-e356.	0.3	3
91	The complicated relationships of heparinâ€induced thrombocytopenia and platelet factor 4 antibodies with COVIDâ€19. International Journal of Laboratory Hematology, 2021, 43, 547-558.	0.7	20
92	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nature Medicine, 2021, 27, 1362-1366.	15.2	70

#	Article	IF	CITATIONS
93	Recommendations for the clinical and laboratory diagnosis of VITT against COVIDâ€19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 1585-1588.	1.9	127
94	COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis. Diagnostics, 2021, 11, 955.	1.3	49
95	Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases. Journal of Rheumatology, 2021, 48, 1330-1339.	1.0	26
97	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines, 2021, 6, 74.	2.9	198
99	In Response (letter 2). Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105880.	0.7	0
100	Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination. American Journal of Emergency Medicine, 2021, 49, 441.e3-441.e4.	0.7	52
101	<scp>COVID</scp> â€19: vaccination problems. Environmental Microbiology, 2021, 23, 2878-2890.	1.8	46
102	Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ, The, 2021, 373, n1114.	3.0	298
103	COVID-19 vector-based vaccine causing thrombosis. Journal of Biomolecular Structure and Dynamics, 2022, 40, 9568-9570.	2.0	2
104	An observational study to identify the prevalence of thrombocytopenia and antiâ€₽F4/polyanion antibodies in Norwegian health care workers after COVIDâ€19 vaccination. Journal of Thrombosis and Haemostasis, 2021, 19, 1813-1818.	1.9	84
105	Renal Vein Thrombosis and Pulmonary Embolism Secondary to Vaccine-induced Thrombotic Thrombocytopenia (VITT). European Journal of Case Reports in Internal Medicine, 2021, 8, 002692.	0.2	7
106	A rare case of superior ophthalmic vein thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021048.	0.5	23
107	Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood, 2021, 138, 293-298.	0.6	87
108	Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19—The Role of RAGE-RAS Crosstalk. Biomolecules, 2021, 11, 876.	1.8	25
109	Using Nonheparin Anticoagulant to Treat a Near-Fatal Case With Multiple Venous Thrombotic Lesions During ChAdOx1 nCoV-19 Vaccination-Related Vaccine-Induced Immune Thrombotic Thrombocytopenia. Critical Care Medicine, 2021, 49, e870-e873.	0.4	16
110	Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. Frontiers in Immunology, 2021, 12, 649122.	2.2	34
111	Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine. Annals of Internal Medicine, 2021, 174, 1480-1482.	2.0	91
112	Laboratory testing for suspected COVIDâ€19 vaccine–induced (immune) thrombotic thrombocytopenia. International Journal of Laboratory Hematology, 2021, 43, 559-570.	0.7	66

#	Article	IF	CITATIONS
113	Successful Liver Transplantation From a Deceased Donor With Vaccine-Induced Thrombotic Thrombocytopenia Causing Cerebral Venous Sinus and Hepatic Veins Thrombosis After ChAdOx1 nCov-19 Vaccination. Transplantation, 2021, 105, e144-e145.	0.5	11
114	US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA - Journal of the American Medical Association, 2021, 325, 2448.	3.8	463
115	SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. New England Journal of Medicine, 2021, 384, 2254-2256.	13.9	412
116	Understanding VITT(ual) reality. Blood, 2021, 138, 285-286.	0.6	2
117	Malignant middle cerebral artery syndrome with thrombotic thrombocytopenia following vaccination against SARS-CoV-2. Journal of the Intensive Care Society, 2022, 23, 479-484.	1.1	5
118	COVID-19: SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. Hamostaseologie, 2021, 41, 179-182.	0.9	3
119	A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine. American Journal of Case Reports, 2021, 22, e932946.	0.3	45
120	Preparing for COVID-19 Vaccination: Guidances for Healthcare Personnel. Korean Journal of Healthcare-Associated Infection Control and Prevention, 2021, 26, 3-15.	0.1	1
121	Thrombosis and COVID-19 vaccines. Revista Ciencias Em Saude, 2021, 11, 1-2.	0.0	0
122	COVIDâ€19 vaccineâ€associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. European Journal of Haematology, 2021, 107, 173-180.	1.1	114
123	Successful treatment of vaccineâ€induced prothrombotic immune thrombocytopenia (VIPIT). Journal of Thrombosis and Haemostasis, 2021, 19, 1819-1822.	1.9	91
124	COVID-19 vaccination for people with autoimmune inflammatory rheumatic diseases on immunomodulatory therapies. The Cochrane Library, 2021, 2021, .	1.5	0
125	Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine. Brain Hemorrhages, 2021, 2, 165-167.	0.4	22
126	Aspectos clave en la vacunación contra la COVID-19 en pacientes con enfermedad inflamatoria intestinal. Revista Colombiana De Gastroenterologia, 2021, 36, 241-251.	0.1	0
127	The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. Blood, 2021, 138, 992-996.	0.6	37
128	COVIDâ€19 in gastroenterology: Where are we now? Current evidence on the impact of COVIDâ€19 in gastroenterology. United European Gastroenterology Journal, 2021, 9, 750-765.	1.6	18
129	Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination. American Journal of Hematology, 2021, 96, E301-E303.	2.0	21
130	Hemophagocytic lymphohistiocytosis after COVID-19 vaccination. Journal of Hematology and Oncology, 2021, 14, 87.	6.9	42

#	Article	IF	CITATIONS
132	Vaccineâ€induced immune thrombotic thrombocytopenia (VITT) – a novel clinicoâ€pathological entity with heterogeneous clinical presentations. British Journal of Haematology, 2021, 195, 76-84.	1.2	42
133	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thrombosis and Haemostasis, 2021, 121, 992-1007.	1.8	21
134	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3546-3567.	2.0	152
135	Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study. New England Journal of Medicine, 2021, 385, 570-571.	13.9	42
136	Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST). Expert Review of Vaccines, 2021, 20, 1037-1042.	2.0	24
137	Text Mining Approaches to Analyze Public Sentiment Changes Regarding COVID-19 Vaccines on Social Media in Korea. International Journal of Environmental Research and Public Health, 2021, 18, 6549.	1.2	41
138	Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. Blood, 2021, 138, 2106-2116.	0.6	23
139	PF4-Dependent Immunoassays in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: Results of an Interlaboratory Comparison. Thrombosis and Haemostasis, 2021, 121, 1622-1627.	1.8	36
140	A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy. Vaccines, 2021, 9, 618.	2.1	5
141	Global covid-19 vaccine rollout and safety surveillance—how to keep pace. BMJ, The, 2021, 373, n1416.	3.0	17
142	Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. , 2021, 9, e002932.		7
144	Coronavirus disease 2019 vaccination in transplant recipients. Current Opinion in Infectious Diseases, 2021, 34, 275-287.	1.3	15
145	Updates on the coronavirus disease 2019 vaccine and consideration in children. Clinical and Experimental Pediatrics, 2021, 64, 328-338.	0.9	8
146	ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Reports, 2021, 14, e243931.	0.2	38
148	Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine. JAMA - Journal of the American Medical Association, 2021, 325, 2445.	3.8	20
149	Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 384, 2202-2211.	13.9	795
150	First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nature Medicine, 2021, 27, 1290-1297.	15.2	205
151	The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601.	1.2	3

\sim			n		
(17	ΓΔΤΙ	ON	RE	'PO	D.L
\sim	. /				1X I.

#	Article	IF	CITATIONS
152	Response to correspondence in reference to the previously published Epub manuscript: immune thrombocytopenic purpura after SARS oVâ€2 vaccine. British Journal of Haematology, 2021, 194, e95-e96.	1.2	0
153	Correspondence in reference to the previously published Epub manuscript: immune thrombocytopenic purpura after SARSâ€CoVâ€2 vaccine. British Journal of Haematology, 2021, 194, e93-e95.	1.2	3
154	COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis, 2021, 24, 755-788.	3.7	114
156	Economic evaluation for mass vaccination against COVID-19. Journal of the Formosan Medical Association, 2021, 120, S95-S105.	0.8	38
157	Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. Internal and Emergency Medicine, 2021, 16, 1113-1119.	1.0	28
158	Transplantation Outcome in Recipients Engrafted With Organs Recovered From the First French Deceased Donor With a SARS-COV-2 Vaccine-induced Thrombotic Thrombocytopenia. Transplantation, 2021, 105, e84-e86.	0.5	3
159	Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19. SN Comprehensive Clinical Medicine, 2021, 3, 2093-2108.	0.3	9
161	The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. Journal of Thrombosis and Haemostasis, 2021, 19, 2094-2095.	1.9	4
162	COVID-19 mRNA Vaccine and Myocarditis. European Journal of Case Reports in Internal Medicine, 2021, 8, 002681.	0.2	43
164	Cerebral venous sinus thrombosis 2Âweeks after the first dose of mRNA SARS-CoV-2 vaccine. Acta Neurochirurgica, 2021, 163, 2359-2362.	0.9	32
165	COVID-19 and Kounis Syndrome: Deciphering Their Relationship. Balkan Medical Journal, 2021, 38, 145-149.	0.3	13
166	Inflammation, Infection and Venous Thromboembolism. Circulation Research, 2021, 128, 2017-2036.	2.0	94
167	SARS-CoV-2 vaccines: Lights and shadows. European Journal of Internal Medicine, 2021, 88, 1-8.	1.0	90
168	Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States. Vaccines, 2021, 9, 673.	2.1	53
169	Splanchnic Vein Thrombosis With Thrombopenia in a Young Otherwise Healthy Patient. Gastroenterology, 2023, 164, 893-895.	0.6	2
170	Vaccineâ€induced thrombotic thrombocytopenia following <scp>Ad26.COV2.S</scp> vaccine in a man presenting as acute venous thromboembolism. American Journal of Hematology, 2021, 96, E346-E349.	2.0	19
171	Vaccineâ€ i nduced Immune Thrombocytopenia and Thrombosis (VITT). Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12529.	1.0	68
172	A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2. Blood Advances, 2021, 5, 2569-2574.	2.5	35

#	Article	IF	Citations
174	The statistical risk of diagnosing coincidental acquired hemophilia A following antiâ€&ARS oVâ€₽ vaccination. Journal of Thrombosis and Haemostasis, 2021, 19, 2360-2362.	1.9	29
175	Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage after SARS-CoV-2-Vaccination in Vaccine Induced Thrombotic Thrombocytopenia—VITT. Journal of Clinical Medicine, 2021, 10, 2777.	1.0	26
176	COVID-19-Associated Cardiovascular Complications. Diseases (Basel, Switzerland), 2021, 9, 47.	1.0	45
179	COVID-19 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey. Vaccines, 2021, 9, 678.	2.1	15
180	Vaccineâ€induced immune thrombotic thrombocytopenia: Consider IVIG batch in the treatment. Journal of Thrombosis and Haemostasis, 2021, 19, 1838-1839.	1.9	13
181	Vaccinations and Autoimmune Diseases. Vaccines, 2021, 9, 815.	2.1	45
183	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 239-254.	0.2	40
185	Autoimmune Hematologic Disorders in Two Patients After mRNA COVID-19 Vaccine. HemaSphere, 2021, 5, e618.	1.2	15
186	Tolosa-Hunt Syndrome Presenting After COVID-19 Vaccination. Cureus, 2021, 13, e16791.	0.2	15
187	Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres. Therapie, 2021, 76, 369-373.	0.6	26
188	Exercise Caution with ChAdOx1 COVID-19 Vaccination in Chronic Budd-Chiari Syndrome with a Thrombophilic Genetic Predisposition. Journal of Clinical and Experimental Hepatology, 2021, , .	0.4	3
189	Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis. Frontiers in Pharmacology, 2021, 12, 708665.	1.6	15
190	Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel. Infection Control and Hospital Epidemiology, 2022, 43, 3-11.	1.0	21
191	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Medicine, 2021, 19, 173.	2.3	156
192	Cutaneous thrombosis associated with skin necrosis following Oxfordâ€AstraZeneca COVIDâ€19 vaccination. Clinical and Experimental Dermatology, 2021, 46, 1610-1612.	0.6	17
193	Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. Journal of Thrombosis and Haemostasis, 2021, 19, 2314-2317.	1.9	45
194	SARS-CoV-2 and Autoimmune Cytopenia. Hemato, 2021, 2, 463-476.	0.2	7
195	SVM Communications: Vaccine-induced immune thrombotic thrombocytopenia (VITT) – what the vascular medicine physician should know. Vascular Medicine, 2021, 26, 579-581.	0.8	3

#	Article	IF	CITATIONS
196	Thoracic Anesthesia during the COVID-19 Pandemic: 2021 Updated Recommendations by the European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC) Thoracic Subspecialty Committee. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 3528-3546.	0.6	6
197	Early approval of COVID-19 vaccines: Pros and cons. Human Vaccines and Immunotherapeutics, 2021, 17, 3288-3296.	1.4	14
200	Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report. TH Open, 2021, 05, e315-e318.	0.7	11
201	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. Inflammopharmacology, 2021, 29, 1331-1346.	1.9	7
203	Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine. Annals of Hematology, 2022, 101, 717-719.	0.8	26
204	Thrombosis and thrombocytopaenia after ChAdOx1 nCoV-19 vaccination: a single UK centre experience. BMJ Case Reports, 2021, 14, e243894.	0.2	24
205	Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nature Medicine, 2021, 27, 1530-1535.	15.2	276
206	COVIDâ€19 and immunothrombosis: emerging understanding and clinical management. British Journal of Haematology, 2021, 194, 518-529.	1.2	42
207	The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic. Pharmaceutical Medicine, 2021, 35, 203-213.	1.0	11
208	Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Vaccines, 2021, 9, 825.	2.1	57
209	Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. BMJ Case Reports, 2021, 14, e243975.	0.2	29
210	Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 103028.	0.9	20
212	Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature, 2021, 596, 565-569.	13.7	218
213	An Epitope Platform for Safe and Effective HTLV-1-Immunization: Potential Applications for mRNA and Peptide-Based Vaccines. Viruses, 2021, 13, 1461.	1.5	6
214	Vaccineâ€induced immune thrombotic thrombocytopenia after vaccination against Covidâ€19: A clinical dilemma for clinicians and patients. Reviews in Medical Virology, 2022, 32, e2273.	3.9	33
215	COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?. Biomolecules, 2021, 11, 1020.	1.8	28
216	Successful treatment of vaccineâ€induced prothrombotic immune thrombocytopenia (VIPIT): COMMENT from Roberge, et al Journal of Thrombosis and Haemostasis, 2021, 19, 2091-2092.	1.9	0
217	COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan. Radiology Case Reports, 2021, 16, 1819-1821.	0.2	14

#	Article	IF	CITATIONS
218	European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination. European Stroke Journal, 2021, 6, 239698732110308.	2.7	17
219	Covid-19 vaccine- induced thrombosis and thrombocytopenia-a commentary on an important and practical clinical dilemma. Progress in Cardiovascular Diseases, 2021, 67, 105-107.	1.6	23
220	Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. Journal of Autoimmunity, 2021, 121, 102662.	3.0	124
221	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 2021, 27, 1525-1529.	15.2	363
222	Unusual Fever, Headache, and Abdominal Pain in a Healthy Woman. Gastroenterology, 2021, 161, 1387-1389.	0.6	4
225	Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first cerebral MRI scan. Stroke and Vascular Neurology, 2021, 6, 668-670.	1.5	21
226	The Spike of SARS-CoV-2: Uniqueness and Applications. Frontiers in Immunology, 2021, 12, 663912.	2.2	14
227	Vaccinating Australia: How long will it take?. Vaccine, 2022, 40, 2491-2497.	1.7	8
228	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines, 2021, 9, 712.	2.1	25
229	Cerebral Venous Thrombosis. New England Journal of Medicine, 2021, 385, 59-64.	13.9	77
230	Lack of consideration of sex and gender in COVID-19 clinical studies. Nature Communications, 2021, 12, 4015.	5.8	89
231	Guillainâ€Barré syndrome following ChAdOx1 nCoVâ€19 COVIDâ€19 vaccination: A case series. Neurology and Clinical Neuroscience, 2021, 9, 402-405.	0.2	25
232	First report of a de novo iTTP episode associated with an mRNAâ€based antiâ€COVIDâ€19 vaccination. Journal of Thrombosis and Haemostasis, 2021, 19, 2014-2018.	1.9	52
233	Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. Haematologica, 2021, 106, 3021-3024.	1.7	8
234	Evaluation of laboratory assays for antiâ€platelet factor 4 antibodies after ChAdOx1 nCOVâ€19 vaccination. Journal of Thrombosis and Haemostasis, 2021, 19, 2007-2013.	1.9	107
235	Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine?. Infection, 2021, 49, 1071-1074.	2.3	5
236	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 121-130.	6.3	316
237	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Critical Care Medicine, 2022, 50, e80-e86.	0.4	30

#	Article	IF	CITATIONS
238	COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 506-507.	0.2	17
239	Immune Thrombocytopenic Purpura after vaccination with COVID-19 Vaccine (ChAdOx1 nCov-19). Blood, 2021, 138, 996-999.	0.6	15
240	Acute hyperglycaemic crisis after vaccination against COVIDâ€19: A case series. Diabetic Medicine, 2021, 38, e14631.	1.2	30
242	Middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination. American Journal of Emergency Medicine, 2022, 51, 427.e3-427.e4.	0.7	13
244	Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102184.	1.8	27
245	COVID-19 vaccines and thrombosis with thrombocytopenia syndrome. Expert Review of Vaccines, 2021, 20, 1027-1035.	2.0	24
246	Organ transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia. American Journal of Transplantation, 2021, 21, 4095-4097.	2.6	13
247	Solid organ procurement and transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia. American Journal of Transplantation, 2021, 21, 4098-4101.	2.6	12
248	Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines. European Journal of Internal Medicine, 2021, 89, 22-24.	1.0	19
249	Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia. International Reviews of Immunology, 2022, 41, 438-447.	1.5	34
250	SARSâ€CoVâ€2 vaccineâ€induced prothrombotic immune thrombocytopenia: Promoting awareness to improve patientâ€doctor trust. Journal of Medical Virology, 2021, 93, 5721-5723.	2.5	1
251	Thrombembolic Events in Hospitalized COVID-19 Patients: What is the Role of the Sex?. TH Open, 2021, 05, e411-e414.	0.7	0
252	COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. Biomedicines, 2021, 9, 903.	1.4	5
253	Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination. Stroke and Vascular Neurology, 2021, , svn-2021-001142.	1.5	20
254	Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood, 2021, 138, 1269-1277.	0.6	102
255	Adenovirus-Vectored COVID-19 Vaccine–Induced Immune Thrombosis of Carotid Artery. Neurology, 2021, 97, 716-719.	1.5	32
256	Suggested treatment of serious complications to COVIDâ€19 vaccination with IdeS, a bacterial antibodyâ€cleaving enzyme. Journal of Thrombosis and Haemostasis, 2021, 19, 2363-2364.	1.9	5
257	Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V). BMJ Case Reports, 2021, 14, e243888.	0.2	83

#	Article	IF	CITATIONS
258	Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series. Frontiers in Neurology, 2021, 12, 721146.	1.1	29
259	Perspectives on vaccine induced thrombotic thrombocytopenia. Journal of Autoimmunity, 2021, 121, 102663.	3.0	47
260	Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 385, e11.	13.9	23
262	SARS-CoV-2 vaccine-induced cerebral venous thrombosis. European Journal of Internal Medicine, 2021, 89, 19-21.	1.0	10
263	Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain and Therapy, 2021, 10, 1309-1330.	1.5	28
264	Antiâ€PF4 testing for vaccineâ€induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: Results from a UK National External Quality Assessment Scheme exercise April 2021. Journal of Thrombosis and Haemostasis, 2021, 19, 2263-2267.	1.9	18
265	Estado actual del diagnóstico y tratamiento de la trombocitopenia inducida por heparina (TIH). Medicina ClÃnica, 2022, 158, 82-89.	0.3	2
266	Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage Following an mRNA COVID-19 Vaccination: Are These Reports Merely Co-Incidental?. American Journal of Case Reports, 2021, 22, e933397.	0.3	20
267	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. Vaccines, 2021, 9, 836.	2.1	15
270	COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers, 2021, 13, 3573.	1.7	39
272	Laboratory testing for post ChAdOx1 nCOVâ€19 vaccination VITT: A challenge. Comment on: Recommendations for the clinical and laboratory diagnosis of VITT against COVIDâ€19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 2355-2357.	1.9	3
273	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thrombosis Research, 2021, 203, 163-171.	0.8	52
276	Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2021, 326, 332.	3.8	37
277	Adaptive Immunity and the Risk of Autoreactivity in COVID-19. International Journal of Molecular Sciences, 2021, 22, 8965.	1.8	35
278	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Npj Vaccines, 2021, 6, 104.	2.9	241
280	The Impact of COVID-19 on Conspiracy Hypotheses and Risk Perception in Italy: Infodemiological Survey Study Using Google Trends. JMIR Infodemiology, 2021, 1, e29929.	1.0	26
281	Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia. Cell Death and Disease, 2021, 12, 762.	2.7	19
282	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. Npj Vaccines, 2021, 6, 97.	2.9	175

	Сітл	CITATION REPORT	
#	Article	IF	Citations
283	Uncommon thrombotic complications after SARS-CoV-2 vaccination. Vnitrni Lekarstvi, 2021, 67, 297-3	02. 0.1	0
285	Buyer beware: The risks of donor-derived vaccine-induced thrombosis and thrombocytopenia. American Journal of Transplantation, 2021, 21, 3829-3830.	2.6	5
286	Activation of circulating platelets in vaccineâ€induced thrombotic thrombocytopenia and its reversal by intravenous immunoglobulin. British Journal of Haematology, 2022, 196, 234-237.	1.2	13
287	Vaccineâ€induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12578.	1.0	18
288	Deterioration of vaccineâ€induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12572.	1.0	11
289	COVID-19 Vaccination Issues in Solid Organ Transplant Recipients. Vestnik Medicinskogo Instituta REAVIZ Reabilitaciâ, Vraĕl Zdorovʹe, 2021, 11, 5-14.	0.1	Ο
290	Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis. Lancet, The, 2021, 398, 577-578.	6.3	49
291	Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thrombosis Research, 2021, 204, 40-51.	0.8	72
292	A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization. Vaccines, 2021, 9, 903.	2.1	10
293	SARS CoV-2 Vaccination Autoimmunity, Antibody Dependent Covid-19 Enhancement and Other Potent Risks: Beneath the Tip of the Iceberg. International Journal of Pulmonary & Respiratory Sciences, 2021, 5, .	tial 0.1	2
294	Therapeutic plasma exchange (TPE) as a plausible rescue therapy in severe vaccine-induced immune thrombotic thrombocytopenia. Transfusion and Apheresis Science, 2021, 60, 103174.	0.5	17
295	COVID 19 and vaccine safety. Journal of Education, Health and Sport, 2021, 11, 313-321.	0.0	Ο
297	Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis. International Journal of Molecular Sciences, 2021, 22, 8562.	1.8	20
299	<scp>COVID</scp> â€19 Vaccineâ€Associated Cerebral Venous Thrombosis in Germany. Annals of Neu 2021, 90, 627-639.	rology, 2.8	122
300	Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, .	0.6	10
301	Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, The, 2021, 374, n1931.	3.0	217
302	Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia. Nature Communications, 2021, 12, 4663.	5.8	47
303	Myocarditis With COVID-19 mRNA Vaccines. Circulation, 2021, 144, 471-484.	1.6	620

#	ARTICLE	IF	Citations
304	To clot or not to clot? Ad is the question—Insights on mechanisms related to vaccineâ€induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis, 2021, 19, 2845-2856.	1.9	16
305	Thrombocytopenia in COVID-19: Focused Summary of Current Understanding of Mechanisms and Clinical Implications. Journal of Pediatric Hematology/Oncology, 2021, 43, 243-248.	0.3	3
306	Comparison of percent adjusted versus predefined incremental argatroban dosing nomograms in patients with heparin induced thrombocytopenia. Thrombosis Update, 2021, 4, 100060.	0.4	0
308	EDTA-Induced Pseudothrombocytopenia up to 9 Months after Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity. Laboratory Medicine, 2022, 53, 206-209.	0.8	5
310	Interpretation of vaccine associated neurological adverse events: a methodological and historical review. Journal of Neurology, 2022, 269, 493-503.	1.8	7
311	Predicted B Cell Epitopes Highlight the Potential for COVID-19 to Drive Self-Reactive Immunity. Frontiers in Bioinformatics, 2021, 1, .	1.0	10
312	Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination. Radiology, 2022, 302, 319-325.	3.6	6
314	COVID vaccines and blood clots: what researchers know so far. Nature, 2021, 596, 479-481.	13.7	12
315	Three cases of acute venous thromboembolism in females following vaccination for COVID-19. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, , .	0.9	23
316	Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination – A risk–benefit analysis for peopleÂ<Â60Âyears in Australia. Vaccine, 2021, 39, 4784-4787.	1.7	25
317	Vaccine-induced pseudothrombocytopenia after Ad26.COV2.S vaccination. Annals of Hematology, 2022, 101, 927-928.	0.8	3
319	COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis. Journal of Neurology, 2022, 269, 1774-1775.	1.8	25
320	COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. Journal of the American Academy of Dermatology, 2021, 85, 1274-1284.	0.6	82
321	Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: Fraternal—Not Identical—Twins. Thrombosis and Haemostasis, 2021, 121, 1558-1561.	1.8	5
322	Modeling the Effects of Intravasal Administration of AstraZeneca ChAdOx1 nCoV-19 Vaccine on Human Platelets. Thrombosis and Haemostasis, 2021, 121, 1681-1683.	1.8	2
323	Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia. Neuroradiology Journal, 2022, 35, 247-249.	0.6	9
324	Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. Journal of Autoimmunity, 2021, 122, 102685.	3.0	53
325	Vaccineâ€induced immune thrombotic thrombocytopenia presenting with normal platelet count. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12596.	1.0	12

#	Article	IF	CITATIONS
326	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews Immunology, 2021, 21, 626-636.	10.6	777
327	COVID-19 vaccines approved in the European Union: current evidence and perspectives. Expert Review of Vaccines, 2021, 20, 1195-1199.	2.0	6
328	Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia. Clinical and Experimental Pediatrics, 2021, 64, 400-405.	0.9	4
329	Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female. Cureus, 2021, 13, e16871.	0.2	9
330	Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines, 2021, 9, 857.	2.1	49
332	The coronavirus disease 2019 (COVID-19) pandemic—Looking back and looking forward. Infection Control and Hospital Epidemiology, 2021, 42, 1-6.	1.0	Ο
333	Platelet Surface Protein Expression and Reactivity upon TRAP Stimulation after BNT162b2 Vaccination. Thrombosis and Haemostasis, 2022, 122, 1706-1711.	1.8	9
334	Rapidly established guidelines for the diagnosis and management of vaccineâ€induced thrombocytopenia and thrombosis (VITT)—Âa doubleâ€edged sword?. British Journal of Haematology, 2021, 195, 9-10.	1.2	1
335	mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. Vaccines, 2021, 9, 918.	2.1	40
336	Perioperative Coronavirus Vaccination—Timing and Implications: A Guidance Document. Annals of Thoracic Surgery, 2021, 112, 1707-1715.	0.7	14
337	Comparison of adverse drug reactions among four COVIDâ€19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. Journal of Thrombosis and Haemostasis, 2021, 19, 2554-2558.	1.9	37
338	COVID-19 infodemics: the role of mainstream and social media. Clinical Microbiology and Infection, 2021, 27, 1568-1569.	2.8	9
339	Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. Haematologica, 2021, 106, 3034-3045.	1.7	24
340	Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience. Anaesthesia, Critical Care & amp; Pain Medicine, 2021, 40, 100889.	0.6	11
341	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. Viruses, 2021, 13, 1687.	1.5	57
342	Postvaccinal Encephalitis after <scp>ChAdOx1 nCov</scp> â€19. Annals of Neurology, 2021, 90, 506-511.	2.8	85
343	Prevalence of thrombocytopenia, anti–platelet factor 4 antibodies and Dâ€dimer elevation in Thai people After ChAdOx1 nCoVâ€19 vaccination. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12580.	1.0	11
344	Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. New England Journal of Medicine, 2021, 385, 1680-1689.	13.9	425

#	Article	IF	CITATIONS
345	Pathogenic Mechanisms of Vaccine-Induced Immune Thrombotic Thrombocytopenia in People Receiving Anti-COVID-19 Adenoviral-Based Vaccines: A Proposal. Frontiers in Immunology, 2021, 12, 728513.	2.2	17
346	Post‣ARS oVâ€2â€vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. European Journal of Neurology, 2021, 28, 3656-3662.	1.7	84
347	Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination. Vaccines, 2021, 9, 956.	2.1	18
348	Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1144-1151.	0.9	37
349	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. Cell Reports, 2021, 36, 109493.	2.9	46
350	Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis. JAMA Cardiology, 2021, 6, 1451.	3.0	85
351	Antiplatelet drugs block platelet activation by VITT patient serum. Blood, 2021, 138, 2733-2740.	0.6	20
353	Vaccine-induced immune thrombotic thrombocytopenia: current evidence, potential mechanisms, clinical implications, and future directions. European Heart Journal Open, 2021, 1, .	0.9	13
355	Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain, 2021, 144, 3576-3588.	3.7	101
356	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1255-1265.	5.2	279
357	Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia. New England Journal of Medicine, 2021, 385, 857-859.	13.9	70
358	Pitfalls at Chemistry of Adenoviral Vector Vaccine against COVID-19 and How to Circumvent It. Advanced Pharmaceutical Bulletin, 2021, , .	0.6	2
359	Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. Thrombosis and Haemostasis, 2021, 121, 1677-1680.	1.8	22
360	Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions. Journal of the Neurological Sciences, 2021, 427, 117532.	0.3	28
361	Assessing the Knowledge and Attitude toward COVID-19 Vaccination in Saudi Arabia. International Journal of Environmental Research and Public Health, 2021, 18, 8185.	1.2	19
364	Trombosis de senos venosos tras vacunación con ChAdOx1 nCov-19. Medicina Intensiva, 2022, 46, 524-527.	0.4	0
365	COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. Frontiers in Cardiovascular Medicine, 2021, 8, 713560.	1.1	76
367	A rare case of vaccine-induced immune thrombosis and thrombocytopenia and approach to management. , 2021, 12, 408.		14

	CHATION		
#	Article	IF	CITATIONS
368	Effect of HIT Components on the Development of Breast Cancer Cells. Life, 2021, 11, 832.	1.1	3
369	Machine learning identifies ICU outcome predictors in a multicenter COVID-19 cohort. Critical Care, 2021, 25, 295.	2.5	39
370	Immune thrombocytopenia following vaccination during the COVID-19 pandemic. Haematologica, 2022, 107, 1193-1196.	1.7	13
371	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends in Cardiovascular Medicine, 2022, 32, 1-9.	2.3	31
372	Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia. European Heart Journal, 2021, 42, 4064-4072.	1.0	49
373	Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines. Journal of Autoimmunity, 2021, 122, 102681.	3.0	34
374	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. Frontiers in Immunology, 2021, 12, 719023.	2.2	28
376	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines, 2021, 9, 848.	2.1	64
377	Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. New England Journal of Medicine, 2021, 385, 720-728.	13.9	156
378	To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination. Expert Review of Vaccines, 2021, 20, 1211-1220.	2.0	85
379	Heparin-induced Thrombocytopenia Diagnosis: A Retrospective Study Comparing Heparin-induced Platelet Activation Test to 14C-serotonin Release Assay. TH Open, 2021, 05, e507-e512.	0.7	5
380	COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia: A Case Series. Cureus, 2021, 13, e17862.	0.2	1
381	Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). European Journal of Internal Medicine, 2021, 91, 90-92.	1.0	25
382	Shell-mediated phagocytosis to reshape viral-vectored vaccine-induced immunity. Biomaterials, 2021, 276, 121062.	5.7	12
383	Controversies and Challenges of Mass Vaccination against SARS-CoV-2 in Italy: Medico-Legal Perspectives and Considerations. Healthcare (Switzerland), 2021, 9, 1163.	1.0	12
384	Comparison of Published Guidelines for the Diagnosis and the Management of Vaccine-Induced Immune Thrombotic Thrombocytopenia. , 2021, 3, e0519.		9
385	Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2021, 80, 1255-1265.	0.5	77
386	Herpes zoster after COVIDâ€19 vaccination—Can the vaccine reactivate latent zoster virus?. Journal of Cosmetic Dermatology, 2021, 20, 3376-3377.	0.8	17

ARTICLE IF CITATIONS Platelet count as an important prognostic factor for vaccine-induced immune thrombotic 387 0.5 4 thrombocytopenia. Blood Research, 2021, 56, 129-133. VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable 388 2.5 19 thrombosis. Blood Advances, 2021, 5, 4662-4665. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the 389 1.0 42 FAPIC score. European Heart Journal, 2021, 42, 4053-4063. Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. International 1.2 Journal of Legal Medicine, 2021, 135, 2335-2345. Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and 391 0.2 5 Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia. Cureus, 2021, 13, e17637. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccineâ€induced thrombotic thrombocytopenia (VITT). Journal of Leukocyte Biology, 2021, , . 1.5 Safety warning for ChAdOx1 nCov-19 vaccine in patients with sickle cell disease. Mediterranean 394 0.5 8 Journal of Hematology and Infectious Diseases, 2021, 13, e2021059. A three-antigen Plasmodium falciparum DNA primeâ€"Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in 1.1 10 healthy malaria-naÃ-ve adults. PLoS ONE, 2021, 16, e0256980. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. New England Journal of Medicine, 2021, 397 13.9 137 385, 1049-1051. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle 1.0 against COVID-19 pandemic: What pathogenesis?. European Journal of Internal Medicine, 2021, 91, 88-89. Risk of heparinoid use in cosmetics and moisturizers in individuals vaccinated against severe acute 399 4 0.9 respiratory syndrome coronavirus 2. Thrombosis Journal, 2021, 19, 67. Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and 400 0.9 vaccine-induced immune thrombotic thrombocytopenia. Thrombosis Journal, 2021, 19, 66. Severe autoimmune hemolytic anemia following receipt of <scp>SARS oV</scp>â€2 <scp>mRNA</scp> 401 0.8 29 vaccine. Transfusion, 2021, 61, 3267-3271. Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia. Stroke, 2021, 1.0 52, 3045-3053. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis 403 0.2 11 with thrombocytopaenia (VITT). BMJ Case Reports, 2021, 14, e245218. COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. Vaccines, 2021, 9, 1097. Thromboinflammatory findings and clinical predictors of mortality in vaccine-induced immune 406 1.0 1 thrombotic thrombocytopenia. European Heart Journal, 2021, 42, 4073-4076. Autoimmunity roots of the thrombotic events after COVID-19 vaccination. Autoimmunity Reviews, 2021, 20, 102941.

#	Article	IF	CITATIONS
408	Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline. Clinical and Molecular Hepatology, 2021, 27, 515-523.	4.5	6
409	Abdominal pain and bilateral adrenal haemorrhage of COVID-19 vaccine-induced immune thrombotic thrombocytopenia. QJM - Monthly Journal of the Association of Physicians, 2021, , .	0.2	3
410	Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with ChAdO×1 nCov-19 vaccine. Haematologica, 2021, 106, 3228-3231.	1.7	2
411	Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low- and middle-income countries. AJOG Global Reports, 2021, 1, 100020.	0.4	6
412	Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. Cancers, 2021, 13, 4750.	1.7	8
413	Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood, 2021, 138, 2256-2268.	0.6	228
414	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. New England Journal of Medicine, 2021, 385, 2348-2360.	13.9	458
415	COVID-19 Vaccine-Induced Thrombosis and Thrombocytopenia: First Confirmed Case from India. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 196-198.	0.3	5
416	Immune Responses against SARS-CoV-2—Questions and Experiences. Biomedicines, 2021, 9, 1342.	1.4	10
417	Vaccines for COVID-19: Where do we stand in 2021?. Paediatric Respiratory Reviews, 2021, 39, 22-31.	1.2	53
418	Thrombocytopenia after COVID-19 vaccination. Journal of Autoimmunity, 2021, 123, 102712.	3.0	15
419	Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech. Frontiers in Medicine, 2021, 8, 751598.	1.2	9
422	Vaccine-Induced Immune Thrombotic Thrombocytopenia with Disseminated Intravascular Coagulation and Death following the ChAdOx1 nCoV-19 Vaccine. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105938.	0.7	32
424	Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. Medicina (Lithuania), 2021, 57, 997.	0.8	9
425	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 1052.	2.1	22
426	ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107 720 doses of ChAdOx1 vaccination in Thailand. Blood Coagulation and Fibrinolysis, 2022, 33, 67-70.	0.5	11
427	Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre. Medicina ClÃnica, 2021, 157, 247-252.	0.3	4
428	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. European Journal of Internal Medicine, 2021, 93, 28-34.	1.0	40

#	Article	IF	CITATIONS
429	Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. JAMA Neurology, 2021, 78, 1314.	4.5	89
430	Ocular Adverse Events After COVID-19 Vaccination. Ocular Immunology and Inflammation, 2021, 29, 1216-1224.	1.0	130
431	SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. Vaccine, 2021, 39, 5769-5779.	1.7	23
432	Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. Journal of Headache and Pain, 2021, 22, 108.	2.5	40
433	Australian and New Zealand approach to diagnosis and management of vaccineâ€induced immune thrombosis and thrombocytopenia. Medical Journal of Australia, 2021, 215, 245.	0.8	29
434	Raynaud's Phenomenon after COVID-19 Vaccination: Causative Association, Temporal Connection, or Mere Bystander?. Case Reports in Dermatology, 2022, 13, 450-456.	0.3	8
435	Acute myocardial infarction and myocarditis following COVID-19 vaccination. QJM - Monthly Journal of the Association of Physicians, 2023, 116, 279-283.	0.2	42
436	A case of COVID-19 vaccination-associated forme fruste purpura fulminans. British Journal of Dermatology, 2022, 186, e1-e1.	1.4	6
437	Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 445-448.	0.9	3
438	Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. International Journal of Hygiene and Environmental Health, 2021, 238, 113851.	2.1	13
439	Acquired Autoimmune Hemophilia Following SARS-CoV-2 Vaccines: Dual-Drug Effects on Blood Coagulation and the Scylla and Charybdis Phenomenon. Thrombosis and Haemostasis, 2021, 121, 1555-1557.	1.8	5
440	Rheumatological complications of Covid 19. Autoimmunity Reviews, 2021, 20, 102883.	2.5	73
441	Establishment of an in vitro thrombogenicity test system with cyclic olefin copolymer substrate for endothelial layer formation. MRS Communications, 2021, 11, 1-9.	0.8	2
442	Thrombosis of the palmar digital vein after Oxfordâ€AstraZeneca COVIDâ€19 vaccination. International Journal of Dermatology, 2021, 60, e469-e471.	0.5	4
443	Vaccine-Induced Thrombocytopenia with Severe Headache. New England Journal of Medicine, 2021, 385, 2103-2105.	13.9	79
444	Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination. JAAD Case Reports, 2021, 15, 11-14.	0.4	17
445	Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study. Thrombosis Research, 2021, 205, 24-28.	0.8	22
446	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. PLoS ONE, 2021, 16, e0257191.	1.1	19

#	Article	IF	CITATIONS
447	Cerebral Venous Sinus Thrombosis, Pulmonary Embolism, and Thrombocytopenia After COVID-19 Vaccination in a Taiwanese Man: A Case Report and Literature Review. Frontiers in Neurology, 2021, 12, 738329.	1.1	5
448	Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. Journal of the Neurological Sciences, 2021, 428, 117607.	0.3	168
450	Cerebral venous sinus thrombosis after vaccination: the UK experience. Lancet, The, 2021, 398, 1107-1109.	6.3	9
451	A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems. Vaccines, 2021, 9, 1086.	2.1	19
452	Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine, 2021, 39, 101061.	3.2	110
453	Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea. Vaccines, 2021, 9, 1096.	2.1	15
454	Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story. Metabolism Open, 2021, 11, 100101.	1.4	41
455	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Lancet Regional Health - Europe, The, 2021, 8, 100171.	3.0	70
456	The known knowns and known unknowns of vaccine-induced thrombotic thrombocytopaenia. Cardiovascular Research, 2021, 117, e147-e150.	1.8	3
457	No Correlation between Anti-PF4 and Anti–SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 385, 1334-1336.	13.9	19
458	Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2. Frontiers in Medicine, 2021, 8, 738049.	1.2	7
459	Clinical use of thrombin generation assays. Journal of Thrombosis and Haemostasis, 2021, 19, 2918-2929.	1.9	43
460	Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination. Frontiers of Medicine, 2021, 15, 938-941.	1.5	2
461	Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New England Journal of Medicine, 2021, 385, 1078-1090.	13.9	735
462	Use of Social Media in the Practice of Medicine. American Journal of Medicine, 2021, , .	0.6	2
463	Label-Free Detection and Characterization of Heparin-Induced Thrombocytopenia (HIT)-like Antibodies. ACS Omega, 2021, 6, 25926-25939.	1.6	2
464	Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study. Vaccine, 2021, 39, 5854-5857.	1.7	17
465	Autoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios. Medicina ClÃnica (English Edition), 2021, 157, 247-252.	0.1	9

#	Article	IF	CITATIONS
466	Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets. Molecules, 2021, 26, 5340.	1.7	3
468	Successful venous thromboprophylaxis in a patient with vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report of the first reported case in Thailand. Thrombosis Journal, 2021, 19, 65.	0.9	8
469	Decline in Pathogenic Antibodies over Time in VITT. New England Journal of Medicine, 2021, 385, 1815-1816.	13.9	56
470	Human adenovirus infections in pediatric population - An update on clinico–pathologic correlation. Biomedical Journal, 2022, 45, 38-49.	1.4	62
471	Cerebral venous thrombosis and myeloproliferative neoplasms: A threeâ€center study of 74 consecutive cases. American Journal of Hematology, 2021, 96, 1580-1586.	2.0	13
472	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. Zeitschrift Fur Rheumatologie, 2021, 80, 33-48.	0.5	13
473	Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 3990-4002.	2.6	124
474	A rare case of COVID-19 vaccine-induced thrombotic thrombocytopaenia (VITT) involving the veno-splanchnic and pulmonary arterial circulation, from a UK district general hospital. BMJ Case Reports, 2021, 14, e244223.	0.2	10
475	Adverse Events Following AstraZeneca COVID-19 Vaccine in Saudi Arabia: A Cross-Sectional Study among Healthcare and Non-healthcare Workers. Intervirology, 2021, , .	1.2	16
476	Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infectious Diseases, The, 2021, 21, 1212-1213.	4.6	111
477	Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet, The, 2021, 398, 1147-1156.	6.3	141
478	Inflammatory myositis after ChAdOx1 vaccination. Lancet Rheumatology, The, 2021, 3, e747-e749.	2.2	29
479	Rare case of COVID-19 vaccine-associated intracranial haemorrhage with venous sinus thrombosis. BMJ Case Reports, 2021, 14, e245092.	0.2	12
480	Myocardial Infarction and Azygos Vein Thrombosis After ChAdOx1 nCoV-19 Vaccination in a Hemodialysis Patient. Cureus, 2021, 13, e18390.	0.2	8
481	Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia. Thrombosis Research, 2021, 206, 14-17.	0.8	5
482	Controversy surrounding the Sputnik V vaccine. Respiratory Medicine, 2021, 187, 106569.	1.3	28
483	Media portrayals of pulmonary embolism. Thrombosis Research, 2021, 206, 52-54.	0.8	0
484	HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination. Current Research in Translational Medicine, 2021, 69, 103312.	1.2	3

#	Article	IF	CITATIONS
485	Successful treatment of acute spleno-porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine. A case report. Journal of Critical Care, 2021, 65, 72-75.	1.0	19
486	Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia. Diagnostic and Interventional Imaging, 2021, 102, 649-650.	1.8	18
487	Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination. Annals of Emergency Medicine, 2021, 78, 511-514.	0.3	22
488	Adult-onset Still's disease following COVID-19 vaccination. Lancet Rheumatology, The, 2021, 3, e678-e680.	2.2	39
489	Self-assembled polymeric micelle as a novel mRNA delivery carrier. Journal of Controlled Release, 2021, 338, 537-547.	4.8	40
491	Effect of a hospital-wide campaign on COVID-19 vaccination uptake among healthcare workers in the context of raised concerns for life-threatening side effects. PLoS ONE, 2021, 16, e0258236.	1.1	7
492	Portal Vein Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) after Covid Vaccination with ChAdOx1 nCoV-19. Ultraschall in Der Medizin, 2021, 42, 551-552.	0.8	9
493	The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action. Vaccine, 2021, 39, 6017-6018.	1.7	11
494	Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARSâ€CoVâ€2 vaccination. European Journal of Neurology, 2022, 29, 339-344.	1.7	38
495	Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106072.	0.7	24
496	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Journal of Autoimmunity, 2021, 124, 102728.	3.0	5
497	Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. American Journal of Emergency Medicine, 2021, 49, 58-61.	0.7	76
498	Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort. Science Bulletin, 2021, 66, 2312-2319.	4.3	26
499	Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group. Thrombosis Research, 2021, 207, 62-65.	0.8	1
500	Mental Health Issues During and After COVID-19 Vaccine Era. Brain Research Bulletin, 2021, 176, 161-173.	1.4	67
501	Chronic inflammation and extracellular matrix-specific autoimmunity following inadvertent periarticular influenza vaccination. Journal of Autoimmunity, 2021, 124, 102714.	3.0	7
502	Vaccine-Induced Immune Thrombotic Thrombocytopenia with Concurrent Arterial and Venous Thrombi Following Ad26.COV2.S Vaccination. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106113.	0.7	9
503	Anticoagulation for COVID-19 Patients: A Bird's-Eye View. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110392.	0.7	10

#	Article	IF	CITATIONS
504	Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination. Journal of Korean Medical Science, 2021, 36, e245.	1.1	12
505	A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: male versus female outcomes. Journal of Advanced Pharmacy Education and Research, 2021, 11, 51-56.	0.2	21
506	An unusual presentation of acute deep vein thrombosis after the Moderna COVID-19 vaccine—a case report. Annals of Translational Medicine, 2021, 9, 0-0.	0.7	18
507	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. Pediatric Infection and Vaccine, 2021, 28, 7.	0.1	7
508	Vaccine-Induced Immune Thrombotic Thrombocytopenia: First Case Report in South Korea. Journal of		

#	Article	IF	CITATIONS
522	Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient. Acta Haematologica, 2021, , 1-4.	0.7	2
523	BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees. Frontiers in Medicine, 2021, 8, 760047.	1.2	84
524	Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (<scp>BNT162b2</scp> , <scp>Pfizerâ€BioNTech</scp>). Thoracic Cancer, 2021, 12, 3072-3075.	0.8	4
525	Evaluation of Adverse Reactions to Vaccines. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3584-3597.	2.0	7
526	Cerebral Venous Sinus Thrombosis With Severe Thrombocytopenia. Neurology: Clinical Practice, 2021, 11, e971-e974.	0.8	0
527	COVID-19 vaccines and thrombosis. Internal and Emergency Medicine, 2022, 17, 587-588.	1.0	Ο
528	Prevalence of anti–platelet factor 4/polyanionic antibodies after COVIDâ€19 vaccination with ChAdOx1 nCoVâ€19 and CoronaVac in Thais. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12600.	1.0	8
529	Trastornos de coagulación después de la vacunación ChAdlx1 nCov-19 contra la COVID-19. Revista Peruana De Investigación En Salud, 2021, 5, 329-331.	0.0	0
530	T cell immunity to SARS-CoV-2. Seminars in Immunology, 2021, 55, 101505.	2.7	55
531	New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19. Multiple Sclerosis and Related Disorders, 2022, 57, 103321.	0.9	28
532	Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More. Seminars in Thrombosis and Hemostasis, 2022, 48, 008-014.	1.5	18
533	COVID-19 ("coronavirus disease 2019") und kein Ende?. DGNeurologie, 2021, 4, 433-434.	0.0	0
534	Lessons from vaccine-induced immune thrombotic thrombocytopenia. Nature Reviews Immunology, 2021, 21, 753-755.	10.6	27
535	Successful treatment of thromboses of major arteries after ChAdOx1 nCov-19 vaccination. Neurological Research and Practice, 2021, 3, 52.	1.0	8
536	Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine. BMJ Case Reports, 2021, 14, e246049.	0.2	20
537	Signal transduction pathway involved in platelet activation in immune thrombotic thrombocytopenia after COVID-19 vaccination. Haematologica, 2021, , .	1.7	3
538	Is VITT really a HIT. Nature Immunology, 2021, 22, 1352-1353.	7.0	8
539	VITT, COVID-19 and the Expert Haematology Panel: The story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme. Clinical Medicine, 2021, 21, e600-e602.	0.8	9

#	Article	IF	CITATIONS
540	The art and science of the thrombosis with thrombocytopenia syndrome. Clinical Medicine, 2021, 21, e603-e603.	0.8	1
541	Update on Coronavirus 2019 Vaccine Guidelines for Transplant Recipients. Transplantation Proceedings, 2022, 54, 1399-1404.	0.3	16
542	Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination. BMJ Case Reports, 2021, 14, e246580.	0.2	17
543	Imaging findings in a patient with suspected vaccine induced immune thrombotic thrombocytopenia. BJR case Reports, 2022, 8, 20210138.	0.1	2
544	Autoimmune screening before adenovirus vector-based DNA vaccine in women may avoid underuse for all the subjects. Neurological Sciences, 2021, 42, 5421-5423.	0.9	0
545	Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. International Journal of Molecular Sciences, 2021, 22, 10791.	1.8	20
546	First report of COVID-19 vaccine induced flare of compensated congenital thrombotic thrombocytopenic purpura. Blood Coagulation and Fibrinolysis, 2022, 33, 71-73.	0.5	9
547	Multiple sites of arterial thrombosis in a 35-year old patient after ChAdOx1 (AstraZeneca) vaccination, requiring emergent femoral and carotid surgical thrombectomy. Annals of Vascular Surgery, 2021, , .	0.4	4
548	Update on the COVID-19 Vaccine Research Trends: A Bibliometric Analysis. Infection and Drug Resistance, 2021, Volume 14, 4237-4247.	1.1	17
549	Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res 2021 in press. Thrombosis Research, 2021, 207, 158-160.	0.8	1
550	The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2. Vaccines, 2021, 9, 1163.	2.1	28
551	Rapid Detection and Inhibition of SARSâ€CoVâ€2â€5pike Mutationâ€Mediated Microthrombosis. Advanced Science, 2021, 8, e2103266.	5.6	11
552	Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2. Frontiers in Immunology, 2021, 12, 666813.	2.2	2
553	MODERNA mRNA-1273 vaccine-associated myopericarditis in a patient with a subclinical autoimmune predisposition. Journal of Cardiology Cases, 2021, 24, 227-229.	0.2	7
554	Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US. Infection, 2022, 50, 531-536.	2.3	16
555	Vaccines against COVID-19: Priority to mRNA-Based Formulations. Cells, 2021, 10, 2716.	1.8	17
556	Thrombosis in pre- and post-vaccination phase of COVID-19. European Heart Journal Supplements, 2021, 23, E184-E188.	0.0	5
557	Diffuse prothrombotic syndrome after ChAdOx1 nCoV-19 vaccine administration: a case report. Journal of Medical Case Reports, 2021, 15, 496.	0.4	11

ARTICLE IF CITATIONS Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccination. 558 6 1.8 Journal of Neurology, 2022, 269, 583-586. Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines. 1.5 Neurology, 2021, 97, e2136-e2147. The COVID-19 pandemic: viral variants and vaccine efficacy. Critical Reviews in Clinical Laboratory 561 2.7 61 Sciences, 2022, 59, 66-75. Cerebral Venous Sinus Thrombosis After BNT162b2 mRNA COVID-19 Vaccination. Cureus, 2021, 13, e18775. Deep Venous Thrombosis after Ad26.COV2.S Vaccination in Adult Male. Case Reports in Critical Care, 563 0.2 2 2021, 2021, 1-2. Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases. Vaccines, 2021, 9, 1147. 564 2.1 Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues. Molecular Therapy - Methods and 565 1.8 5 Clinical Development, 2021, 23, 418-423. Shedding Light on the Possible Link between ADAMTS13 and Vaccineâ€"Induced Thrombotic 9 566 1.8 Thrombocytopenia. Cells, 2021, 10, 2785. Immunogenicity and efficacy of            heterologous ChAdOx1–BNT162b2 vaccination, Nature, 2021, 600, 567 701-706. Haematuria, a widespread petechial rash, and headaches following the Oxford AstraZeneca ChAdOx1 0.2 nCoV-19 Vaccination. BMJ Case Reports, 2021, 14, e245440. Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. 569 2.6 11 International Journal of Pharmaceutics, 2021, 610, 121212. Vaccineâ€induced immune thrombosis and thrombocytopenia syndrome following adenovirusâ€vectored severe acute respiratory syndrome coronavirus 2 vaccination: a novel hypothesis regarding mechanisms and implications for future vaccine development. Immunology and Cell Biology, 2021, 99, 1.0 1006-1010. Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women 571 0.9 5 Receiving Estrogen. BioMed Research International, 2021, 2021, 1-4. GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in 5.8 younger and older adults. Science Translational Medicine, 2022, 14, eabj1996. GFHT proposals on the practical use of argatroban â€" With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT). Anaesthesia, Critical Care & amp; Pain Medicine, 2021, 40, 573 0.6 6 100963. A case series of vaccineâ€induced thrombotic thrombocytopenia in a London teaching hospital. British

CITATION REPORT

575	Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World Journal of Cardiology, 2021, 13, 556-565.	0.5	1	
576	Neuro-ophthalmic complications with ChAdOx1 nCoV-19 vaccine-induced thrombocytopenia and	0.2	2	

thrombosis. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-4.

574

Journal of Clinical Pharmacology, 2021, , .

#	Article	IF	CITATIONS
579	Ischemic stroke after AstraZeneca (Covid-19) vaccination. Journal of King Abdulaziz University, Islamic Economics, 2021, 42, 1136-1139.	0.5	11
580	Hypercoagulability of COVID-19 and Neurological Complications: A Review. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106163.	0.7	8
581	Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thrombosis Research, 2021, 207, 126-130.	0.8	15
582	Covid-19 vaccination, adverse events, and detection of antibodies. Thrombosis Research, 2021, 207, 131-133.	0.8	1
583	Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines. Journal of the Neurological Sciences, 2021, 430, 120030.	0.3	27
584	Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. Journal of Autoimmunity, 2021, 125, 102742.	3.0	42
585	Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study. Thrombosis Research, 2021, 208, 1-3.	0.8	7
586	Models for SARS-CoV-2 associated thrombocytopenia associated with hemophagocytic histiocytes. Medical Hypotheses, 2021, 157, 110700.	0.8	1
587	Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report. Thrombosis Research, 2021, 208, 14-17.	0.8	4
588	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. International Immunopharmacology, 2021, 101, 108232.	1.7	14
589	Cerebral venous sinus thrombosis after ChAdOx1 vaccination: the first case of definite thrombosis with thrombocytopenia syndrome from India. BMJ Case Reports, 2021, 14, e246455.	0.2	15
590	Vaccine-Induced Thrombotic Thrombocytopenia: Insights from Blood Smear. Thrombosis and Haemostasis, 2021, 121, 1696-1698.	1.8	6
592	Imaging Findings of COVID-19–Related Cardiovascular Complications. Cardiac Electrophysiology Clinics, 2022, 14, 79-93.	0.7	4
593	Vaccine development and technology for SARS oVâ€2: Current insight. Journal of Medical Virology, 2022, 94, 878-896.	2.5	8
594	Clinical Features and Management of COVID-19 Associated Hypercoagulability. Cardiac Electrophysiology Clinics, 2021, 14, 41-52.	0.7	2
595	Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). Clinical Chemistry and Laboratory Medicine, 2022, 60, 7-17.	1.4	28
596	COVID-19 vaccine mandate for healthcare workers in the United States: a social justice policy. Expert Review of Vaccines, 2022, 21, 37-45.	2.0	22
597	Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine. Science Advances, 2021, 7, eabj8065.	4.7	31

#	Article	IF	CITATIONS
598	<scp>COVID</scp> â€19 vaccine hesitancy: a unique set of challenges. Internal Medicine Journal, 2021, 51, 1987-1989.	0.5	18
600	Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. Vaccine, 2021, 39, 7052-7057.	1.7	24
601	Viral vector-based vaccines against SARS-CoV-2. Exploration of Immunology, 2021, , 295-308.	1.7	4
602	Lobar bleeding with ventricular rupture shortly after first dosage of an mRNA-based SARS-CoV-2 vaccine. Brain Hemorrhages, 2022, 3, 26-28.	0.4	5
603	Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews. Frontiers in Immunology, 2021, 12, 740048.	2.2	7
604	Neurological autoimmune diseases following vaccinations against SARSâ€CoVâ€2: a case series. European Journal of Neurology, 2022, 29, 555-563.	1.7	85
605	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematology,the, 2021, 8, e934-e946.	2.2	46
606	Cerebral venous sinus thrombosis associated with COVIDâ€19 vaccineâ€induced thrombocytopenia: Improvement in mortality rate over time. European Journal of Neurology, 2022, 29, 1-2.	1.7	5
607	Serious complications of COVID-19 vaccines: A mini-review. Metabolism Open, 2021, 12, 100145.	1.4	25
608	Case Presentations of the Harvard Affiliated Emergency Medicine Residencies: A Case of Bleeding During Infection with COVID-19. Journal of Emergency Medicine, 2021, , .	0.3	1
609	Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Lithuania), 2021, 57, 1163.	0.8	9
611	Atypical Hemolytic Uremic Syndrome after ChAdOx1 nCoV-19 Vaccination in a Patient with Homozygous CFHR3/CFHR1 Gene Deletion. Nephron, 2021, , 1-5.	0.9	12
613	Restoring vision using optogenetics without being blind to the risks. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 41-45.	1.0	16
614	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medicinski Podmladak, 2021, 72, 20-29.	0.2	3
615	COVID-19 Vaccines: A weapon for global security. APIK Journal of Internal Medicine, 2021, 9, 200.	0.1	0
617	A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine. Cureus, 2021, 13, e18985.	0.2	13
618	Thrombosis and Thrombocytopenia Syndrome Causing Isolated Symptomatic Carotid Occlusion after Covid-19 Vaccine. Thrombosis and Haemostasis, 2022, 122, 300-303.	1.8	7
619	COVIDâ€19 coagulopathies: Human blood proteins mimic SARSâ€CoVâ€2 virus, vaccine proteins and bacterial coâ€infections inducing autoimmunity. BioEssays, 2021, 43, e2100158.	1.2	17

#	Article	IF	CITATIONS
620	The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vectorâ€based COVIDâ€19 vaccination: Where there is much light, the shadow is deep. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12609.	1.0	1
621	Bilateral Thalamic Stroke: A Case of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) or a Coincidence Due to Underlying Risk Factors?. Cureus, 2021, 13, e18977.	0.2	4
622	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. Scientific Reports, 2021, 11, 21849.	1.6	26
623	Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Lancet Microbe, The, 2022, 3, e11-e20.	3.4	25
624	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. Epidemiology and Infection, 2021, 149, 1-24.	1.0	43
625	Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework. Vaccine, 2021, 39, 7429-7440.	1.7	19
626	Brain venography performance following the pause of Ad.26.COV2.S COVID-19 vaccine administration. Journal of Thrombosis and Thrombolysis, 2022, 53, 359-362.	1.0	2
627	An Insight into the Role of Postmortem Immunohistochemistry in the Comprehension of the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-Related Thrombotic Adverse Events: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 12024.	1.8	5
628	A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Medica, 2021, 63, 324-331.	0.2	8
629	Vaccine-induced immune thrombotic thrombocytopenia: definition, risks with different vaccines, and regulatory responses. Obstetrics, Gynecology and Reproduction, 2021, 15, 562-575.	0.2	1
630	COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. American Journal of the Medical Sciences, 2022, 363, 465-475.	0.4	16
631	COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thrombosis Research, 2021, 208, 129-137.	0.8	12
632	VITT after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 385, 2202-2203.	13.9	13
634	Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies. Acta Cardiologica Sinica, 2021, 37, 355-364.	0.1	14
636	Thrombotic events and COVID-19 vaccines. International Journal of Tuberculosis and Lung Disease, 2021, 25, 701-707.	0.6	4
637	Cooling down VITT with IVIG. Blood, 2021, 138, 921-922.	0.6	3
638	SARS-CoV-2 vaccines-induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?. Revista De Saude Publica, 2021, 55, 70.	0.7	1
639	The Ethics of Selective Mandatory Vaccination for COVID-19. Public Health Ethics, 2022, 15, 74-86.	0.4	11

# 640	ARTICLE Regeneration through platelet rich plasma – A cell therapy with a path full of milestones, controversies and cautions!. Indian Dermatology Online Journal, 2021, 12, 1.	IF 0.2	Citations
641	Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient. Internal Medicine, 2022, 61, 407-412.	0.3	20
642	Splanchnic vein thrombosis-related mortality in the Veneto region (Italy), 2008–2019: Retrospective analysis of epidemiological data. Thrombosis Research, 2022, 209, 41-46.	0.8	3
643	Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). Lancet Regional Health - Europe, The, 2022, 12, 100274.	3.0	15
644	Thrombotic events and COVID-19 vaccines. International Journal of Tuberculosis and Lung Disease, 2021, 25, 701-707.	0.6	19
645	SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?. Revista De Saude Publica, 2021, 55, 70.	0.7	2
646	Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematology,the, 2022, 9, e73-e80.	2.2	114
647	Thromboembolic and hemorrhagic risks after vaccination against SARS-CoV-2: a systematic review and meta-analysis of randomized controlled trials. Thrombosis Journal, 2021, 19, 86.	0.9	15
648	Genital necrosis with cutaneous thrombosis after COVIDâ€19 mRNA vaccination. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	7
649	The effectiveness and safety of the use of antithrombotic therapy in COVID-19. Ambulatornaâ Hirurgiâ, 2021, 18, 17-30.	0.0	4
651	Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database. Vaccines, 2021, 9, 1326.	2.1	38
652	COVID-19 Induced Cardiovascular Complications and Recent Therapeutic Advances. European Journal of Medical and Health Sciences, 2021, 3, 17-22.	0.1	2
653	Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?. Life, 2021, 11, 1220.	1.1	8
654	The Use of COVID-19 Vaccines in Patients with SLE. Current Rheumatology Reports, 2021, 23, 79.	2.1	32
655	A Case of COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 776-778.	0.4	9
656	Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia—A Case Report. Vaccines, 2021, 9, 1344.	2.1	26
657	Disc edema in one eye and central serous chorioretinopathy in the other eye shortly after <scp>AstraZeneca COVID</scp> â€19 vaccination. Kaohsiung Journal of Medical Sciences, 2022, 38, 283-285.	0.8	10
658	Adenovirus vector-based vaccine for infectious diseases. Drug Metabolism and Pharmacokinetics, 2022, 42, 100432.	1.1	55

CITA	ELONI.	DEDO	DT
		Repo	K

#	Article	IF	CITATIONS
659	Case Report: Take a Second Look: Covid-19 Vaccination-Related Cerebral Venous Thrombosis and Thrombotic Thrombocytopenia Syndrome. Frontiers in Neurology, 2021, 12, 763049.	1.1	4
660	Subclinical thrombotic thrombocytopenic purpura after vaccination with ChAdOx1 nCoV-19. Blood Research, 2021, , .	0.5	1
661	Those Donor Leucocytes Again? This Time It's VITT!. Liver Transplantation, 2022, 28, 164-166.	1.3	0
662	Comments on Thrombosis After Vaccination: The Leader Sequence of the Spike Protein Might Be Responsible for Thrombosis and Antibody-Mediated Thrombocytopenia. Viral Immunology, 2021, , .	0.6	1
663	Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19. Journal of Anesthesia, Analgesia and Critical Care, 2021, 1, .	0.5	1
664	Vaccine-Induced Thrombotic Thrombocytopenia Due to Coronavirus Disease 2019 Vaccine From a Deceased Donor: A Case Report. Transplantation Proceedings, 2022, 54, 1534-1538.	0.3	5
665	COVIDâ€19 vaccines mixâ€andâ€match: The concept, the efficacy and the doubts. Journal of Medical Virology, 2022, 94, 1294-1299.	2.5	69
666	Utilization of health care services before and after media attention about fatal side effects of the AstraZeneca vaccine: a nation-wide register-based event study. BMC Health Services Research, 2021, 21, 1229.	0.9	1
667	Case report: Pituitary apoplexy after COVID-19 vaccination. Medicina ClÃnica, 2022, 158, 498-499.	0.3	16
668	Low clinical utility of testing for antiâ€platelet factor 4 in asymptomatic individuals after ChAdOx1 nCoVâ€19 vaccine. International Journal of Laboratory Hematology, 2022, 44, 424-429.	0.7	8
669	COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations. Asia-Pacific Journal of Ophthalmology, 2021, 10, 521-529.	1.3	23
670	Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2022, 53, 954-958.	1.0	4
671	New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review. CEN Case Reports, 2022, 11, 242-246.	0.5	20
673	Acuteâ€onset polyradiculoneuropathy after <scp>SARS oV2</scp> vaccine in the West and North Midlands, United Kingdom. Muscle and Nerve, 2022, 65, 233-237.	1.0	21
674	Sustained Delivery of SARSâ€CoVâ€2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold. Advanced Healthcare Materials, 2022, 11, e2101714.	3.9	17
675	Delayed hypersensitivity to the Comirnaty coronavirus disease 2019 vaccine presenting with pneumonitis and rash. Annals of Allergy, Asthma and Immunology, 2022, 128, 321-322.	0.5	3
676	A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials. Vaccines, 2021, 9, 1322.	2.1	30
677	Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. Frontiers in Immunology, 2021, 12, 779453.	2.2	59

#	Article	IF	CITATIONS
678	COVID-19, gender and estroprogestins, what do we know?. European Journal of Contraception and Reproductive Health Care, 2022, 27, 67-74.	0.6	13
679	Possibility of exosomeâ€ʿbased coronavirus disease 2019 vaccine (Review). Molecular Medicine Reports, 2021, 25, .	1.1	18
680	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. Vaccines, 2021, 9, 1317.	2.1	35
681	Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview. Cardiology and Therapy, 2022, 11, 13-21.	1.1	45
682	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. Frontiers in Microbiology, 2021, 12, 761887.	1.5	21
683	Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature. Neurology International, 2021, 13, 622-639.	1.3	13
684	A Review Article on Vaccine Development and Therapeutics Approach Against SARS-CoV-2. The Open Covid Journal, 2021, 1, 117-138.	0.4	0
685	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. JAMA Network Open, 2021, 4, e2135044.	2.8	18
686	COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis. Frontiers in Immunology, 2021, 12, 729251.	2.2	63
687	Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination. Neurological Sciences, 2022, 43, 41-43.	0.9	11
688	Red urine and a red herring – diagnosing rare diseases in the light of the COVID-19 pandemic. Zeitschrift Fur Gastroenterologie, 2022, 60, 1326-1331.	0.2	4
689	Thrombosis and thrombocytopenia after HPV vaccination. Journal of Thrombosis and Haemostasis, 2022, 20, 700-704.	1.9	29
690	COVID-19 vaccines and herpes infection. Medicina ClÃnica (English Edition), 2021, , .	0.1	1
691	Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: a report of three cases. Journal of NeuroInterventional Surgery, 2022, 14, 853-858.	2.0	11
692	Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2. Thrombosis and Haemostasis, 2022, 122, 304-307.	1.8	11
693	A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis. Annals of Hepatology, 2022, 27, 100590.	0.6	3
694	<i>Ex Vivo</i> and <i>In Vivo</i> CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26). Journal of Virology, 2022, 96, JVI0082621.	1.5	9
695	COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. Translational Research, 2022, 241, 25-40.	2.2	5

# 696	ARTICLE Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current	IF 0.4	CITATIONS
090	practices. Thrombosis Update, 2021, 5, 100086.	0.4	4
697	Patients presenting high fever with lymphadenopathy after COVID-19 vaccination were diagnosed with hemophagocytic lymphohistiocytosis. Infectious Diseases, 2022, 54, 303-307.	1.4	16
698	Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia. Cells, 2021, 10, 3386.	1.8	35
699	AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice. Vaccine, 2022, 40, 192-195.	1.7	9
700	VITT(al) insights into vaccine-related clots. Blood, 2021, 138, 2159-2160.	0.6	2
701	ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances, 2021, 7, eabl8213.	4.7	112
702	Pharmacovigilance in Covid-19 vaccines. E3S Web of Conferences, 2021, 319, 01012.	0.2	0
703	An overview of the ongoing challenges in SARS-CoV-2 global control. German Journal of Microbiology, 2021, 1, 1-18.	0.3	17
704	Vacinas para covid-19 e complicações tromboembólicas. Jornal Vascular Brasileiro, 2021, 20, e20210167.	0.1	1
705	Platelet Dropping, Bleeding and the Requirement of New Round Treatment After Inactivated COVID-19 Vaccination in the ITP-Associated Patients in China: A Population-Based Retrospective Study. SSRN Electronic Journal, 0, , .	0.4	0
706	Complement-related thrombosis. Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 695-707.	0.1	0
707	Thrombosis with Thrombocytopenia Syndrome After Administration of AZD1222 or Ad26.COV2.S Vaccine for COVID-19: A Systematic Review. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110684.	0.7	12
708	The Impact of COVID-19 on Patients With ADPKD. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110564.	0.6	1
709	Central retinal vein occlusion in a young healthy COVID-19 patient: A case report and literature review. Middle East African Journal of Ophthalmology, 2021, 28, 199.	0.5	8
710	Atypical Roles of the Chemokine Receptor ACKR3/CXCR7 in Platelet Pathophysiology. Cells, 2022, 11, 213.	1.8	4
711	Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment. Journal of Thoracic Oncology, 2022, 17, 16-18.	0.5	0
712	SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. Thrombosis Research, 2022, 209, 75-79.	0.8	7
713	Newâ€onset autoimmune phenomena postâ€COVIDâ€19 vaccination. Immunology, 2022, 165, 386-401.	2.0	288

#	Article	IF	CITATIONS
714	Bilateral adrenal haemorrhage with renal infarction after ChAdOx1 nCoV-19 AstraZeneca vaccination. BJR case Reports, 2022, 8, .	0.1	2
715	Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2. Vaccines, 2022, 10, 69.	2.1	10
716	Outcomes of patients with thromboembolic events following coronavirus disease 2019 AstraZeneca vaccination: a systematic review and meta-analysis. Blood Coagulation and Fibrinolysis, 2022, 33, 90-112.	0.5	14
717	Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England. Lancet Regional Health - Europe, The, 2022, 13, 100260.	3.0	35
718	Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy. Biomedicine and Pharmacotherapy, 2022, 146, 112518.	2.5	27
719	Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. Biomedicine and Pharmacotherapy, 2022, 146, 112527.	2.5	34
720	Proposed mechanism for rare thrombotic events after use of some Covid-19 vaccines. Medical Hypotheses, 2022, 159, 110756.	0.8	2
721	Thrombodynamics parameters in individuals vaccinated against SARS-CoV-2. Profilakticheskaya Meditsina, 2021, 24, 24.	0.2	6
722	Thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 715-722.	0.1	0
723	A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. Journal of Korean Medical Science, 2021, 36, e306.	1.1	13
724	COVID-19 vaccine hesitancy in oncology patients. , 2021, 1, 34.		0
725	One in a million: COVID-19 vaccine-induced thrombosis with thrombocytopaenia syndrome. South African General Practitioner, 2021, 2, 76-80.	0.0	1
726	COVID-19 in der Neurologie: Das klinische Bild wird prĤiser. , 0, , .		2
727	Pulmonary Embolism in Vaccine-Induced Thrombotic Thrombocytopaenia: Under-Reported?. European Medical Journal Respiratory, 0, , 79-85.	1.0	1
728	Acute Myocardial Infarction with Microthrombi in Cardiac Small Vessels after COVID-19 Vaccination (ChAdOx1 nCov-19): A Case Report. Korean Journal of Legal Medicine, 2021, 45, 127-132.	0.1	2
729	Dabigatran as alternative therapy in prothrombotic immune thrombocytopenia induced by the AstraZeneca SARS-Cov-2 vaccineÂÂ. Journal of Cardiology & Current Research, 2021, 14, 145-146.	0.1	0
730	Clots in unusual places: lots of stress, limited data, critical decisions. Hematology American Society of Hematology Education Program, 2021, 2021, 92-99.	0.9	2
731	Immune Thrombocytopenia Induced by the Chimpanzee Adenovirus-Vectored Vaccine against SARS-CoV-2 Infection. Vaccines, 2021, 9, 1486.	2.1	6

#	Article	IF	CITATIONS
732	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	6.1	180
733	Is Molecular Mimicry between hPF4 and SARS-CoV-2 Spike Protein a Potential Basis for Autoimmune Responses in Vaccinated and Naturally Infected Patients?. Seminars in Thrombosis and Hemostasis, 2023, 49, 103-104.	1.5	5
734	Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity. Drug Safety, 2022, 45, 137-144.	1.4	15
735	Contraception in the COVID-19 pandemic: recommendations from the Korean society of contraception and reproductive health. Obstetrics and Gynecology Science, 2022, , .	0.6	4
737	Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens. Molecular Therapy, 2022, 30, 1822-1849.	3.7	24
738	Cerebral arterial and venous thrombosis due to COVID-19 vaccine-induced immune thrombotic thrombocytopenia. BMJ Case Reports, 2022, 15, e245445.	0.2	13
739	Vasculature-on-a-chip platform with innate immunity enables identification of angiopoietin-1 derived peptide as a therapeutic for SARS-CoV-2 induced inflammation. Lab on A Chip, 2022, 22, 1171-1186.	3.1	27
740	Central retinal vein occlusion post-COVID-19 vaccination. Indian Journal of Ophthalmology, 2022, 70, 308.	0.5	33
741	The Underestimated Role of Platelets in Severe Infection a Narrative Review. Cells, 2022, 11, 424.	1.8	9
742	Morbilliform rashes as an unusual manifestation of vaccine-induced immune thrombotic thrombocytopenia. Journal of the Formosan Medical Association, 2022, , .	0.8	1
743	Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS. Antibodies, 2022, 11, 7.	1.2	15
744	Current status of diagnosis and treatment of heparin-induced thrombocytopenia (HIT). Medicina ClÃnica (English Edition), 2022, 158, 82-89.	0.1	0
745	Acute Kidney Injury With Endothelial Injury and Podocytopathy Following COVID-19 Vaccination. Transplantation, 2022, Publish Ahead of Print, .	0.5	2
746	Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women. Expert Review of Vaccines, 2022, , 1-3.	2.0	0
747	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
748	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. International Journal of Biological Sciences, 2022, 18, 459-472.	2.6	65
749	To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review. Egyptian Journal of Bronchology, 2022, 16, .	0.3	1
750	<scp>COVID</scp> â€19 vaccines and risks of hematological abnormalities: Nested case–control and selfâ€controlled case series study. American Journal of Hematology, 2022, 97, 470-480.	2.0	37

#	Article	IF	CITATIONS
751	Acute liver failure after vaccination against of COVID-19; a case report and review literature. Respiratory Medicine Case Reports, 2022, 35, 101568.	0.2	10
752	Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET). BMC Infectious Diseases, 2022, 22, 70.	1.3	4
753	Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Frontiers in Immunology, 2022, 13, 811020.	2.2	11
754	Autoimmune Encephalitis as an Adverse Event of COVID-19 Vaccination. Journal of Clinical Neurology		

39

#	Article	IF	CITATIONS
769	Initial Mix-and-Match COVID-19 Vaccination Perceptions, Concerns, and Side Effects across Canadians. Vaccines, 2022, 10, 93.	2.1	7
770	Massive cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 serum: case report of a successful multidisciplinary approach. Neurological Sciences, 2022, 43, 1499-1502.	0.9	6
771	Occam's Razor and Managing Acute Thrombosis in the COVID-19 Era. Vascular and Endovascular Surgery, 2022, , 153857442110683.	0.3	0
772	Vaccineâ€induced immune thrombotic thrombocytopenia with ChAdOx1 nCoVâ€19 is rare in Asia. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12644.	1.0	9
773	Differential Effects of Platelet Factor 4 (CXCL4) and Its Non-Allelic Variant (CXCL4L1) on Cultured Human Vascular Smooth Muscle Cells. International Journal of Molecular Sciences, 2022, 23, 580.	1.8	6
774	Thrombosis and Haemostasis 2021 Editors' Choice Papers. Thrombosis and Haemostasis, 2022, 122, 163-170.	1.8	2
775	A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson). Therapie, 2022, 77, 734-737.	0.6	3
776	Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Haematologica, 2022, 107, 947-957.	1.7	37
777	Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021. Annals of Internal Medicine, 2022, 175, 513-522.	2.0	93
778	Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVIDâ€19 vaccine. Journal of Thrombosis and Haemostasis, 2022, 20, 961-974.	1.9	12
779	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	2.0	32
780	Global thrombosis test for assessing thrombotic status and efficacy of antithrombotic diet and other conditions. Future Science OA, 2022, 8, FSO788.	0.9	0
781	Prospective Evaluation of Side-Effects Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among Healthcare Workers in Saudi Arabia. Vaccines, 2022, 10, 223.	2.1	17
782	Combined Central Retinal Artery and Vein Occlusion with Ischemic Optic Neuropathy After COVID-19 Vaccination. International Medical Case Reports Journal, 2022, Volume 15, 7-14.	0.3	26
783	COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review. Annals of Thoracic Medicine, 2022, 17, 1.	0.7	6
784	Reply. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 285.	0.9	0
785	SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID. Intestinal Research, 2022, 20, 171-183.	1.0	5
786	The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia. Annals of Internal Medicine, 2022, 175, 604-605.	2.0	6

#	Article	IF	CITATIONS
787	Pfizer/ BioNtech BNT162b2 : adverse events and insights from an Australian mass vaccination clinic for COVID â€19. Internal Medicine Journal, 2022, 52, 121-124.	0.5	10
788	VITT and Second Doses of Covid-19 Vaccine. New England Journal of Medicine, 2022, 386, 95-95.	13.9	38
789	Two Cases of Acute Macular Neuroretinopathy Associated with the Adenovirus-based COVID-19 Vaccine Vaxzevria (Astrazeneca). Ocular Immunology and Inflammation, 2022, 30, 1234-1239.	1.0	11
790	mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2. Frontiers in Immunology, 2021, 12, 821538.	2.2	11
792	Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines. Viruses, 2022, 14, 228.	1.5	6
793	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. Viruses, 2022, 14, 178.	1.5	18
794	Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS ONE, 2022, 17, e0260733.	1.1	60
796	PharmGKB summary. Pharmacogenetics and Genomics, 2022, Publish Ahead of Print, .	0.7	1
797	Adenovirus-based vaccines and thrombosis in pregnancy: A systematic review and meta-analysis. Clinical Infectious Diseases, 2022, , .	2.9	6
798	SARSâ€CoVâ€2â€related and Covidâ€19 vaccineâ€induced thromboembolic events: A comparative review. Revie in Medical Virology, 2022, 32, e2327.	2WS 3.9	8
799	Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors. ACS Nano, 2022, 16, 4426-4443.	7.3	33
800	Case Series: Acute Hemorrhagic Encephalomyelitis After SARS-CoV-2 Vaccination. Frontiers in Neurology, 2021, 12, 820049.	1.1	16
801	Histological and immunohistochemical findings in a fatal case of thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Pathology Research and Practice, 2022, 231, 153796.	1.0	5
802	Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. Journal of Allergy and Clinical Immunology, 2022, 149, 569-578.	1.5	3
803	Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes and Endocrinology,the, 2022, 10, 221-230.	5.5	78
804	Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination. IScience, 2022, 25, 103694.	1.9	5
805	Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States. Frontiers in Public Health, 2021, 9, 756633.	1.3	36
806	Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel. Annals of Internal Medicine, 2022, 175, 541-546.	2.0	23

#	Article	IF	CITATIONS
807	Post COVID-19 Vaccination-Associated Neurological Complications. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 137-154.	1.0	28
808	Coronary thrombo-embolic events after Covid-19 vaccination- a single centre study. Indian Heart Journal, 2022, 74, 131-134.	0.2	12
809	Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. International Journal of Infectious Diseases, 2022, 116, 114-121.	1.5	2
810	Clinical Cardiovascular Adverse Events Reported Post-COVID-19 Vaccination: Are They a Real Risk?. Current Problems in Cardiology, 2022, 47, 101077.	1.1	20
811	Post COVID-19 vaccine deaths - Singapore's early experience. Forensic Science International, 2022, 332, 111199.	1.3	9
812	Bilateral acute macular neuroretinopathy in a young woman after the first dose of Oxford–AstraZeneca COVID-19 vaccine. American Journal of Ophthalmology Case Reports, 2022, 25, 101281.	0.4	8
813	Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine. Thrombosis Research, 2022, 211, 60-62.	0.8	20
814	Late-Onset Vaccine-Induced Immune Thombotic Thrombocytopenia (VITT) with Cerebral Venous Sinus Thrombosis. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106311.	0.7	3
815	Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review. Journal of Primary Care and Community Health, 2022, 13, 215013192210744.	1.0	20
816	Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia. International Journal of Molecular Medicine, 2022, 49, .	1.8	4
818	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. European Heart Journal, 2022, 43, 1157-1172.	1.0	297
819	Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination. RMD Open, 2022, 8, e001902.	1.8	7
820	Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient. Blood, 2022, 139, 1903-1907.	0.6	30
821	COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study. Vaccines, 2022, 10, 253.	2.1	6
822	Serious events following COVIDâ€19 vaccination with ChAdOx1 nCoVâ€19 vaccine (Vaxzevria): A short case series from Iran. Clinical Case Reports (discontinued), 2022, 10, e05390.	0.2	6
823	COVID-19 vaccines: Considering sex differences in efficacy and safety. Contemporary Clinical Trials, 2022, 115, 106700.	0.8	35
824	COVID-19 Coagulopathy: From Pathogenesis to Treatment. Acta Haematologica, 2022, 145, 282-296.	0.7	19
825	Clinical picture of VITT. Seminars in Hematology, 2022, 59, 76-79.	1.8	4

#	Article	IF	CITATIONS
826	Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS oVâ€2 vaccination. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2381-2392.	2.7	14
827	Heparin-Functionalized Adsorbents Eliminate Central Effectors of Immunothrombosis, including Platelet Factor 4, High-Mobility Group Box 1 Protein and Histones. International Journal of Molecular Sciences, 2022, 23, 1823.	1.8	15
828	Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients. JAMA Internal Medicine, 2022, 182, 165.	2.6	100
829	Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia. Pathology, 2022, 54, 254-261.	0.3	12
831	Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases. Vaccines, 2022, 10, 232.	2.1	21
832	Thromboembolic events following mRNA vaccines for COVID 19: a case series. Journal of Thrombosis and Thrombolysis, 2022, 53, 971-973.	1.0	4
833	Case Report: Hypergranular Platelets in Vaccine-Induced Thrombotic Thrombocytopenia After ChAdOx1 nCov-19 Vaccination. Frontiers in Cardiovascular Medicine, 2022, 9, 824601.	1.1	2
834	Adrenal haemorrhage and infarction in the setting of vaccine-induced immune thrombocytopenia and thrombosis after SARS-CoV-2 (Oxford–AstraZeneca) vaccination. Endocrinology, Diabetes and Metabolism Case Reports, 2022, 2022, .	0.2	4
835	Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation. , 2022, 1, 132-141.		18
836	Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT. Thrombosis Journal, 2022, 20, 4.	0.9	6
837	Persistence of Ad26.COV2.Sâ€associated vaccineâ€induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. American Journal of Hematology, 2022, 97, 519-526.	2.0	26
838	The role of anti-platelet factor 4 antibodies and platelet activation tests in patients with vaccine-induced immune thrombotic thrombocytopenia: Brief report on a comparison of the laboratory diagnosis and literature review. Clinica Chimica Acta, 2022, 529, 42-45.	0.5	8
839	Epidemiology of VITT. Seminars in Hematology, 2022, 59, 72-75.	1.8	30
840	The Coronavirus pandemic – 2022: Viruses, variants & vaccines. Cytokine and Growth Factor Reviews, 2022, 63, 1-9.	3.2	31
841	Retinal Vein Occlusion Following Two Doses of mRNA-1237 (Moderna) Immunization for SARS-Cov-2: A Case Report. Ophthalmology and Therapy, 2022, 11, 453-458.	1.0	21
842	The state of complement in COVID-19. Nature Reviews Immunology, 2022, 22, 77-84.	10.6	159
843	The race for a COVID-19 vaccine: where are we up to?. Expert Review of Vaccines, 2022, 21, 355-376.	2.0	11
844	Post-COVID-19 vaccination occurrence of splenic infarction due to arterial thrombosis. BMJ Case Reports, 2021, 14, e243846.	0.2	5

#	Article	IF	CITATIONS
845	Platelet ACKR3/CXCR7 favors antiplatelet lipids over anÂatherothrombotic lipidome and regulates thromboinflammation. Blood, 2022, 139, 1722-1742.	0.6	17
846	First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine – case report. BMC Nephrology, 2021, 22, 411.	0.8	22
847	Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 5876.	1.0	38
849	Potential Anionic Substances Binding to Platelet Factor 4 in Vaccine-Induced Thrombotic Thrombocytopenia of ChAdOx1-S Vaccine for SARS-CoV-2. Frontiers in Immunology, 2021, 12, 782335.	2.2	3
851	NOTTO guidelines for vaccine-induced thrombotic thrombocytopenia in organ donation and transplantation. Indian Journal of Transplantation, 2022, 16, 3.	0.0	1
852	Safety and Immunogenicity of a Candidate Tuberculosis Vaccine ChAdOx1-85A Delivered by Aerosol Versus Intramuscular Route in Healthy Adults in a Phase 1, Double-Blind Randomized Controlled Trial. SSRN Electronic Journal, 0, , .	0.4	0
853	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
854	Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers. Infection and Chemotherapy, 2022, 54, 140.	1.0	4
855	Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. Alexander Saltanov Intensive Care Herald, 2022, , 5-140.	0.2	7
856	Polymyalgia Rheumatica Following COVID-19 Vaccination. Internal Medicine, 2022, 61, 1775-1777.	0.3	6
857	A Case Report of Thrombotic Thrombocytopenia After ChAdOx1 nCov-19 Vaccination and Heparin Use During Hemodialysis. Journal of Korean Medical Science, 2022, 37, e75.	1.1	3
858	Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine: Reply to comment from Doyle et al Journal of Thrombosis and Haemostasis, 2022, 20, 783-784.	1.9	1
859	Vaccination for SARS-CoV-2 in Hematological Patients. Acta Haematologica, 2022, 145, 257-266.	0.7	8
860	Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Vaccines, 2022, 10, 359.	2.1	11
861	Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein. Haematologica, 2022, 107, 1687-1692.	1.7	10
862	Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. Platelets, 2022, 33, 640-644.	1.1	7
863	Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in Immunology, 2022, 13, 828053.	2.2	11
864	Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque. Archives of Toxicology, 2022, 96, 1437-1453.	1.9	5

		CITATION REPORT		
#	Article		IF	CITATIONS
865	Platelet-activating anti-PF4 disorders: An overview. Seminars in Hematology, 2022, 59,	, 59-71.	1.8	25
866	Is COVID-19 vaccination beneficial or harmful to endothelial cells?. Hypertension Resea	arch, 2022, , .	1.5	1
867	The Safety of Anti-SARS-CoV-2 Vaccines: Vigilance Is Still Required. Journal of Clinical N 11, 1248.	1edicine, 2022,	1.0	2
868	Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Demonstrated?. Vaccines, 2022, 10, 308.	Relationship Been	2.1	21
869	Homologous and Heterologous Anti-COVID-19 Vaccination Does Not Induce New-Ons Autoantibodies Typically Accompanying Lupus Erythematodes, Rheumatoid Arthritis, C Antiphospholipid Syndrome. Vaccines, 2022, 10, 333.	et Formation of Celiac Disease and	2.1	15
870	Myelin Oligodendrocyte Glycoprotein Antibody–Mediated Optic Neuritis Following O Vaccination. Journal of Neuro-Ophthalmology, 2023, 43, e123-e125.	COVID-19	0.4	4
871	Immune-Mediated Platelet Activation in COVID-19 and Vaccine-Induced Immune Thror Thrombocytopenia. Frontiers in Immunology, 2022, 13, 837629.	nbotic	2.2	14
872	Scientific method and the COVID pandemic. Journal of Thrombosis and Haemostasis, 2	2022, 20, 547-548.	1.9	Ο
873	Cerebral venous sinus thrombosis after adenovirus-vectored COVID-19 vaccination: re- neurological-neuroradiological procedure. Neuroradiology, 2022, 64, 865-874.	view of the	1.1	8
874	Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination. Case Reports in 2022, 2022, 1-4.	Critical Care,	0.2	2
875	COVID-19: vaccines, efficacy and effects on variants. Current Opinion in Pulmonary Mo 180-191.	edicine, 2022, 28,	1.2	24
876	Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine. Tu Haematology, 2022, 39, 74-75.	ırkish Journal of	0.2	5
877	Vocal fold paralysis following first dose of Oxford-AstraZeneca coronavirus disease 20 Journal of Laryngology and Otology, 2022, 136, 466-468.	19 vaccine.	0.4	4
878	A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals w COVID-19 adenoviral-vector-based vaccines. Journal of Thrombosis and Thrombolysis, 2		1.0	18
880	New presentations and exacerbations of immune thrombocytopenia after coronavirus vaccinations: the Taiwan experience. Platelets, 2022, 33, 531-535.	disease 2019	1.1	7
881	Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Po Adverse Effects Based on Predisposing Factors. Vaccines, 2022, 10, 366.		2.1	39
882	Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective. 10, 342.	Vaccines, 2022,	2.1	48
883	Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Tren Cardiovascular Medicine, 2022, 32, 249-256.	ds in	2.3	28

#	Article	IF	CITATIONS
884	Propensity-Score-Matched Evaluation of Adverse Events Affecting Recovery after COVID-19 Vaccination: On Adenovirus and mRNA Vaccines. Vaccines, 2022, 10, 284.	2.1	4
885	COVID-19, Vaccines, and Thrombotic Events: A Narrative Review. Journal of Clinical Medicine, 2022, 11, 948.	1.0	18
886	Platelet size as a mirror for the immune response after SARS oVâ€2 vaccination. Journal of Thrombosis and Haemostasis, 2022, 20, 818-820.	1.9	1
887	Gender and ABO Blood Type Differences in a Unicentric Group of University Professors in Southern Italy Who Received the Vaxzevria COVID-19 Vaccine: A Cross-Sectional Survey of Vaccine Side Effects, Attitudes, and Hesitation. Vaccines, 2022, 10, 373.	2.1	2
888	Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2. Vaccines, 2022, 10, 322.	2.1	8
889	Posterior Scleritis Following COVID-19 Vaccination: A Case Report. Ocular Immunology and Inflammation, 2023, 31, 638-640.	1.0	7
891	COVID-19 Vaccination and The Eye. American Journal of Ophthalmology, 2022, 240, 79-98.	1.7	32
892	Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). Seminars in Hematology, 2022, 59, 97-107.	1.8	30
893	Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Infection, 2022, 50, 1399-1404.	2.3	20
894	Epidemiology of cerebral venous sinus thrombosis and cerebral venous sinus thrombosis with thrombocytopenia in the United States, 2018 and 2019. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12682.	1.0	9
895	Vaccine-Induced Thrombotic Thrombocytopenia: A Case of Splanchnic Veins Thrombosis. Cureus, 2022, 14, e23507.	0.2	2
896	A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. , 2022, 1, 223-237.		20
897	Anticoagulation Strategies in Critically III Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 2961-2967.	0.6	4
898	The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19. Frontiers in Immunology, 2022, 13, 807934.	2.2	24
900	Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study. Thrombosis and Haemostasis, 2022, 122, 1352-1360.	1.8	6
901	COVID-19 and COVID-19 vaccination: Observations on thrombosis and thrombocytopenia. Trends in Cardiovascular Medicine, 2022, , .	2.3	1
902	Vaccine based on folded receptor binding domainâ€PreS fusion protein with potential to induce sterilizing immunity to SARSâ€CoVâ€2 variants. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2431-2445.	2.7	16
903	Laboratory testing for VITT antibodies. Seminars in Hematology, 2022, 59, 80-88.	1.8	11

#	Article	IF	CITATIONS
906	Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis. Blood, 2022, 139, 2553-2560.	0.6	20
907	Effect of Severe Limb Purpura Following the Administration of COVID-19 Vaccination on a Diabetic Foot Requiring Amputation: A Case Report. Journal of Korean Foot and Ankle Society, 2022, 26, 48-53.	0.0	Ο
908	VITT with inactivated SARS-CoV-2 vaccine – index case. Human Vaccines and Immunotherapeutics, 2022, 18, 1-2.	1.4	11
909	Observations on improving COVID-19 vaccination responses in kidney transplant recipients: heterologous vaccination and immunosuppression modulation. Kidney International, 2022, 101, 642-645.	2.6	20
910	Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases, 2022, 119, 130-139.	1.5	31
911	Vaccine-induced thrombotic thrombocytopenia (VITT): first report from India. Thrombosis Journal, 2022, 20, 11.	0.9	10
912	Central nervous system adverse events after ChAdOx1 vaccination. Neurological Sciences, 2022, 43, 3503-3507.	0.9	16
913	Myelin Oligodendrocyte Glycoprotein-Associated Disorders Post-ChAdOx1 Vaccination. Cureus, 2022, 14, e23197.	0.2	2
914	Thrombotic events following Covid-19 vaccines compared to Influenza vaccines. European Journal of Internal Medicine, 2022, 99, 82-88.	1.0	10
915	Upper Limb Ischemia Due to Arterial Thrombosis after COVID-19 Vaccination. Case Reports in Medicine, 2022, 2022, 1-4.	0.3	3
916	Role of imaging in rare COVID-19 vaccine multiorgan complications. Insights Into Imaging, 2022, 13, 44.	1.6	4
917	Arterial and venous thrombotic stroke after ChAdOx1 nCoV-19 vaccine. Clinical Medicine, 2022, 22, 184-186.	0.8	6
918	SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?. Vaccines, 2022, 10, 444.	2.1	11
919	Vaccinations and ITP: keep on track(ing). Blood, 2022, 139, 1437-1438.	0.6	Ο
920	Case Report: Recanalization of Branch Retinal Artery Occlusion Due to Microthrombi Following the First Dose of SARS-CoV-2 mRNA Vaccination. Frontiers in Pharmacology, 2022, 13, 845615.	1.6	11
921	Polyradiculitis and encephalomyelitis in the same patient following a SARS-CoV-2 vaccination. Neurological Research and Practice, 2022, 4, 11.	1.0	Ο
922	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. Journal of Microbiology, 2022, 60, 308-320.	1.3	6
923	The precautionary principle in the COVID-19 vaccination campaign: The complicated relationship between the scientific community, medicines regulatory agencies and citizens. European Journal of Internal Medicine, 2022, , .	1.0	1

#	Article	IF	CITATIONS
924	Best practice approaches to outpatient management of people living with Parkinson's disease during the COVID-19 pandemic. Journal of Neural Transmission, 2022, 129, 1377-1385.	1.4	2
925	Stroke after COVIDâ€19 vaccination. Acta Neurologica Scandinavica, 2022, 145, 787-788.	1.0	6
926	Attention for sex in COVID-19 trials: a review of regulatory dossiers. BMJ Global Health, 2022, 7, e008173.	2.0	6
927	The COVIDâ€19 vaccine intentions of Australian disability support workers. Australian and New Zealand Journal of Public Health, 2022, 46, 314-321.	0.8	3
928	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. International Journal of Molecular Sciences, 2022, 23, 3338.	1.8	11
929	Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore. JAMA Network Open, 2022, 5, e222940.	2.8	22
930	The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopenia. Clinical Medicine, 2022, 22, 140-144.	0.8	7
931	<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood, 2022, 140, 274-284.	0.6	9
932	Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients. Vaccines, 2022, 10, 480.	2.1	15
933	Safety and Efficacy of the Common Vaccines against COVID-19. Vaccines, 2022, 10, 513.	2.1	27
934	Vaccine-Induced Thrombotic Thrombocytopenia: A Case Report. Cureus, 2022, 14, e23196.	0.2	1
935	Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. Blood, 2022, 139, 2720-2724.	0.6	16
936	Case Report: Severe Rhabdomyolysis and Multiorgan Failure After ChAdOx1 nCoV-19 Vaccination. Frontiers in Immunology, 2022, 13, 845496.	2.2	13
937	Immune thrombocytopenia purpura flare post COVID-19 vaccine. Annals of Medicine and Surgery, 2022, 75, 103164.	0.5	8
938	Patients With Suspected Severe Adverse Reactions to COVID-19 Vaccination Admitted to Intensive Care Unit: A Case Report. Frontiers in Medicine, 2022, 9, 823837.	1.2	2
939	Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers. BMC Infectious Diseases, 2022, 22, 291.	1.3	26
940	Cardiovascular Complications of COVID-19 Vaccines. Frontiers in Cardiovascular Medicine, 2022, 9, 840929.	1.1	20
941	Venous Sinus Thrombosis due to Vaccine-Induced Thrombotic Thrombocytopenia (VITT): A Case Report. Journal of Stroke Medicine, 0, , 251660852210824.	0.2	1

#	Article	IF	CITATIONS
942	MOG antibody-associated disease after vaccination with ChAdOx1 nCoV-19. Lancet Neurology, The, 2022, 21, 217-218.	4.9	13
943	COVID-19 vaccination in patients with immune thrombocytopenia. Blood Advances, 2022, 6, 1637-1644.	2.5	30
945	A review of adverse effects of COVID-19 vaccines. Infezioni in Medicina, 2022, 30, 1-10.	0.7	18
946	Longitudinal Aspects of VITT. Seminars in Hematology, 2022, 59, 108-114.	1.8	12
947	COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): state of the art. Current Cardiology Reviews, 2022, 18, .	0.6	1
948	Stroke Among SARS-CoV-2 Vaccine Recipients in Mexico: A Nationwide Descriptive Study. Neurology, 2022, , 10.1212/WNL.00000000000200388.	1.5	15
949	Recommendations from the ICM-VTE: General. Journal of Bone and Joint Surgery - Series A, 2022, 104, 4-162.	1.4	14
951	Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland. Vaccines, 2022, 10, 434.	2.1	12
952	The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats. Vaccine, 2022, 40, 1996-2002.	1.7	1
953	Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). Seminars in Hematology, 2022, 59, 89-96.	1.8	31
954	The pathological maelstrom of COVID-19 and cardiovascular disease. , 2022, 1, 200-210.		14
955	Cerebral Venous Thrombosis in Patients With Heparin-Induced Thrombocytopenia a Systematic Review. Stroke, 2022, 53, 1892-1903.	1.0	7
956	Adverse events following vaccination against coronavirus disease 2019. Kosin Medical Journal, 2022, 37, 18-26.	0.1	0
957	Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2. Vaccines, 2022, 10, 516.	2.1	2
959	Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk?. Expert Review of Neurotherapeutics, 2022, , 1-4.	1.4	1
960	Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination. Thrombosis Research, 2022, 214, 21-22.	0.8	2
962	mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People. Viruses, 2022, 14, 748.	1.5	11
963	A Three-Case Series of Thrombotic Deaths in Patients over 50 with Comorbidities Temporally after modRNA COVID-19 Vaccination. Pathogens, 2022, 11, 435.	1.2	5

#	Article	IF	CITATIONS
964	Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. Journal of the Formosan Medical Association, 2022, 121, 766-777.	0.8	22
965	The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies. Haematologica, 2022, 107, 2445-2453.	1.7	7
967	Phenotypic appearance of central retinal vein occlusion post AstraZeneca vaccine. International Journal of Ophthalmology, 2022, 15, 672-673.	0.5	3
968	Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine. Vaccine, 2022, 40, 3072-3084.	1.7	6
969	Fatal thrombotic microangiopathy with rhabdomyolysis as an initial symptom after the first dose of mRNA–1273 vaccine: A case report. International Journal of Infectious Diseases, 2022, 117, 322-325.	1.5	9
970	Characteristics of VITT antibodies in patients vaccinated withÂAd26.COV2.S. Blood Advances, 2023, 7, 246-250.	2.5	18
971	The path towards herd immunity: Predicting COVID-19 vaccination uptake through results from a stated choice study across six continents. Social Science and Medicine, 2022, 298, 114800.	1.8	17
972	Recurrent Anterior Non-necrotizing Scleritis as an Adverse Event of ChAdOx1 nCoV-19 (Vaxzevria) Vaccine. Ocular Immunology and Inflammation, 2022, , 1-3.	1.0	5
973	Ischemic stroke shortly after vaccination against SARS-CoV-2: A case-control study. Journal of the Neurological Sciences, 2022, 436, 120209.	0.3	6
974	Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review. Biomedicine and Pharmacotherapy, 2022, 149, 112843.	2.5	14
975	Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review. Current Problems in Cancer Case Reports, 2022, 6, 100153.	0.1	7
976	Stroke Associated with COVID-19 Vaccines. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106440.	0.7	21
977	Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan. Journal of Clinical Virology, 2022, 150-151, 105156.	1.6	5
978	Acute ischemic stroke after first dose of inactivated COVID-19 vaccine: A case report. Radiology Case Reports, 2022, 17, 1942-1945.	0.2	5
979	Effectiveness and Safety of COVID-19 Vaccine. Trends in the Sciences, 2021, 26, 10_18-10_25.	0.0	0
980	Aortic thrombosis and acute limb ischemia after ChAdOx1 nCov-19 (Oxford-AstraZeneca) vaccination: a case of vaccine-induced thrombocytopenia and thrombosis (VITT). Acta Chirurgica Belgica, 2023, 123, 329-332.	0.2	3
981	Case Report: Adult Onset Still's Disease after vaccination against Covid-19. Wellcome Open Research, 0, 6, 333.	0.9	3
982	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus, 2021, 30, 2276-2285.	0.8	21

#	Article	IF	CITATIONS
983	Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study. PLoS ONE, 2021, 16, e0260638.	1.1	11
984	Vaccineâ€induced immune thrombocytopenia and thrombosis: The decline in antiâ€platelet factor 4 antibodies is assayâ€dependent. British Journal of Haematology, 2021, , .	1.2	5
985	Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton's Tyrosine Kinase. International Journal of Molecular Sciences, 2022, 23, 76.	1.8	5
986	Cerebral Venous Sinus Thrombosis due to Thrombosis with Thrombocytopenia Syndrome Following Ad26.COV2.S: A First Real-World Case Report of a Male Subject. Neurohospitalist, The, 2022, 12, 346-351.	0.3	3
988	Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. Vaccines, 2021, 9, 1478.	2.1	5
990	Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination. Neurology, 2022, 98, .	1.5	19
991	A unique case of splenic rupture secondary to vaccineâ€induced immune thrombocytopenia managed with splenic embolization. ANZ Journal of Surgery, 2021, , .	0.3	2
992	Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine. BMJ Case Reports, 2021, 14, e246200.	0.2	5
993	Platelet Dysregulation in the Pathobiology of COVID-19. Hamostaseologie, 2021, , .	0.9	2
994	COVID-19 and thrombosis: searching for evidence. Hematology American Society of Hematology Education Program, 2021, 2021, 621-627.	0.9	12
995	Balancing benefits and potential risks of vaccination: the precautionary principle and the law of unintended consequences. BMJ Evidence-Based Medicine, 2022, 27, 319-323.	1.7	1
996	Mechanical Thrombectomy for Treatment of Cerebral Venous Sinus Thrombosis in Vaccine-Induced Immune Thrombotic Thrombocytopenia. American Journal of Neuroradiology, 2022, 43, 98-101.	1.2	5
997	On the Safety of the COVID-19 Convalescent Plasma Treatment: Thrombotic and Thromboembolic Concerns. Covid, 2022, 2, 1-4.	0.7	0
998	Qualitative exploration of intentions, concerns and information needs of vaccineâ€hesitant adults initially prioritised to receive COVIDâ€19 vaccines in Australia. Australian and New Zealand Journal of Public Health, 2022, 46, 16-24.	0.8	36
999	Venous Thrombosis and SARS-CoV-2. Hamostaseologie, 2022, 42, 240-247.	0.9	7
1001	Vaccine-induced immune responses against SARS-CoV-2 infections. Exploration of Immunology, 0, , 356-373.	1.7	0
1002	Portal Vein Thrombosis Might Develop by COVID-19 Infection or Vaccination: A Systematic Review of Case-Report Studies. Frontiers in Medicine, 2021, 8, 794599.	1.2	15
1004	Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica, 2022, 107, 1219-1221.	1.7	28

#	Article	IF	CITATIONS
1005	Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection. Molecular Medicine, 2021, 27, 160.	1.9	12
1006	Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome. International Journal of Molecular Sciences, 2022, 23, 93.	1.8	8
1007	Protective Effect of Melatonin Administration against SARS-CoV-2 Infection: A Systematic Review. Current Issues in Molecular Biology, 2022, 44, 31-45.	1.0	7
1008	Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland. BMC Infectious Diseases, 2021, 21, 1275.	1.3	13
1009	Cardiovascular and haematological events post COVIDâ€19 vaccination: A systematic review. Journal of Cellular and Molecular Medicine, 2022, 26, 636-653.	1.6	40
1011	Prothrombotic Phenotype in COVID-19: Focus on Platelets. International Journal of Molecular Sciences, 2021, 22, 13638.	1.8	21
1012	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. Journal of Microbiology and Biotechnology, 2021, 31, 1601-1614.	0.9	8
1013	Management of Vascular Thrombosis in Patients with Thrombocytopenia. Hamostaseologie, 2022, 42, 019-028.	0.9	0
1014	Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?. Human Vaccines and Immunotherapeutics, 2024, 17, 5135-5138.	1.4	11
1015	Disentangling post-vaccination symptoms from early COVID-19. EClinicalMedicine, 2021, 42, 101212.	3.2	8
1016	Cooling down VITT with IVIG. Blood, 2021, 138, 921-922.	0.6	7
1017	A Rare Case of Coronavirus Disease 2019 Vaccine-Associated Cerebral Venous Sinus Thrombosis Treated with Mechanical Thrombectomy. American Journal of Case Reports, 2022, 23, e935355.	0.3	5
1018	Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England. PLoS Medicine, 2022, 19, e1003926.	3.9	51
1019	First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales. PLoS Medicine, 2022, 19, e1003927.	3.9	37
1020	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. Cell Transplantation, 2022, 31, 096368972210902.	1.2	3
1021	Vaccine-induced thrombotic thrombocytopenic purpura. The Journal of Clinical and Scientific Research, 2022, 11, 55.	0.1	0
1022	To aspirate or not to aspirate? Considerations for the COVID-19 vaccines. Pharmacological Reports, 2022, 74, 1223-1227.	1.5	6
1023	Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of	1.1	2

#	Article	IF	CITATIONS
1024	Cerebral Venous Sinus Thrombosis Associated with Vaccine-Induced Thrombotic Thrombocytopenia—A Narrative Review. Clinical and Translational Neuroscience, 2022, 6, 11.	0.4	0
1027	Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. JAMA Network Open, 2022, 5, e227038.	2.8	23
1028	Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers. Vaccine, 2022, 40, 2915-2924.	1.7	5
1029	Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination. Circulation Research, 2022, 130, 1187-1203.	2.0	20
1030	COVID-19 Vaccines: Current and Future Perspectives. Vaccines, 2022, 10, 608.	2.1	26
1031	SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia with Venous Thrombosis, Pulmonary Embolism, and Adrenal Haemorrhage: A Case Report with Literature Review. Vaccines, 2022, 10, 595.	2.1	8
1032	An unusual clinical manifestation of coronavirus disease 2019 in a woman with twin pregnancy: a case report. Journal of Medical Case Reports, 2022, 16, 156.	0.4	1
1034	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. Rheumatology, 2022, 61, SI136-SI142.	0.9	13
1035	Risk of venous thromboembolism after COVIDâ€19 vaccination. Journal of Thrombosis and Haemostasis, 2022, 20, 1638-1644.	1.9	24
1036	Adamalysins in COVID-19 – Potential mechanisms behind exacerbating the disease. Biomedicine and Pharmacotherapy, 2022, 150, 112970.	2.5	6
1037	Cerebral venous thrombosis in post-partum. Visual Journal of Emergency Medicine, 2022, 27, 101351.	0.0	0
1038	Explaining COVID-19 postvaccination-related immune thrombotic thrombocytopenia: a hypothesis-generating <i>in-silico</i> approach. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	0
1039	COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Seminars in Immunopathology, 2022, 44, 375-390.	2.8	15
1040	Manifestation of Herpetic Eye Disease after COVID-19 Vaccine: A UK Case Series. Ocular Immunology and Inflammation, 2022, 30, 1136-1141.	1.0	17
1041	Acquired Hemophilia A Developed Post COVID-19 Vaccine: An Extremely Rare Complication Journal of Medical Cases, 2022, 13, 1-4.	0.4	10
1042	Perceived risk and vaccine hesitancy: Quasiâ€experimental evidence from Italy. Health Economics (United) Tj ETO	Qq1,10.78	34314 rgBT
1043	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). Wiener Klinische Wochenschrift, 2022, 134, 399-419.	1.0	1
1044	COVIDâ€19 disease and vaccination in pregnant and lactating women. American Journal of Reproductive Immunology, 2022, 88, .	1.2	17

#	Article	IF	CITATIONS
1045	Understanding vaccineâ€induced thrombotic thrombocytopenia (VITT). Internal Medicine Journal, 2022, 52, 717-723.	0.5	10
1046	Realâ€world evidence from over one million <scp>COVID</scp> â€19 vaccinations is consistent with reactivation of the varicellaâ€zoster virus. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1342-1348.	1.3	28
1047	Thrombotic thrombocytopenic purpura following administration of the Moderna booster vaccine. BMJ Case Reports, 2022, 15, e247576.	0.2	1
1048	Vaccine-induced thrombosis and thrombocytopaenia with widespread abdominal venous thrombosis, venous ischaemia and bowel oedema. BMJ Case Reports, 2022, 15, e247996.	0.2	1
1049	A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Advances, 2022, 6, 3494-3506.	2.5	17
1050	Live imaging of platelets and neutrophils during antibody-mediated neurovascular thrombosis. Blood Advances, 2022, , .	2.5	1
1051	Clinical care pathway for the evaluation of patients with suspected VITTÂafter ChAdOx1 nCoV-19 vaccination. Blood Advances, 2022, 6, 3315-3320.	2.5	5
1052	COVID-19 vaccine safety surveillance and emerging concerns of vaccine-induced immune thrombotic thrombocytopenia Journal of Geriatric Cardiology, 2021, 18, 952-956.	0.2	0
1053	Plasma exchange as an effective salvage therapy in AZD1222 vaccine-induced thrombotic thrombocytopenia: a case report Blood Transfusion, 2021, , .	0.3	1
1054	Vaccine-Inducted Thrombotic Thrombocytopenia and Covid-19 Vaccines: Case Series. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2022, 43, 49-55.	0.2	1
1055	Inflammatory Bowel Diseases in Renal Transplantat Recipients: A Case Series and Review of the Literature. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2022, 43, 57-63.	0.2	1
1056	Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19. Frontiers in Immunology, 2022, 13, 834988.	2.2	26
1058	İmmune-mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine. Turkish Journal of Haematology, 2021, , .	0.2	3
1059	Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease. Cardiovascular Research, 2022, 118, 2329-2338.	1.8	20
1060	Hormone Therapy in the Era of the COVID-19 Pandemic: A Review. Journal of Menopausal Medicine, 2022, 28, 1.	0.3	3
1061	Relationship between blood clots and COVID-19 vaccines: A literature review. Open Life Sciences, 2022, 17, 401-415.	0.6	6
1062	Antiâ€platelet factor 4 immunoglobulin G levels in vaccineâ€induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12707.	1.0	9
1063	Risk of thrombosis with thrombocytopenia syndrome after COVIDâ€19 vaccination prior to the recognition of vaccineâ€induced thrombocytopenia and thrombosis: A selfâ€controlled case series study in England. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12698.	1.0	8

#	Article	IF	Citations
" 1064	Intravenous Immunoglobulins Promote an Expansion of Monocytic Myeloid-Derived Suppressor Cells (MDSC) in CVID Patients. Journal of Clinical Immunology, 2022, 42, 1093-1105.	2.0	2
1065	Vaccine-induced immune thrombotic thrombocytopenia: why, what, who, and how?. American Journal of Emergency Medicine, 2022, 57, 158-158.	0.7	0
1066	Covid19 vaccination-associated portal vein thrombosis—An interdisciplinary clinical challenge. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101932.	0.7	6
1067	Selective COVID-19 Coinfections in Diabetic Patients with Concomitant Cardiovascular Comorbidities Are Associated with Increased Mortality. Pathogens, 2022, 11, 508.	1.2	2
1068	A Rare Case of COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia in a Young Patient. Cureus, 2022, , .	0.2	1
1069	Platelet Versus Megakaryocyte: Who Is the Real Bandleader of Thromboinflammation in Sepsis?. Cells, 2022, 11, 1507.	1.8	8
1070	Vaccine-induced thrombotic thrombocytopenia: Effect of E3 gene elimination from ds-DNA adenovirus vector?. Medical Hypotheses, 2022, 164, 110864.	0.8	0
1071	Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration. Blood, 2022, 140, 478-490.	0.6	40
1072	Vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccine in an older patient: minireview and a case report. Journal of Infection and Public Health, 2022, 15, 638-642.	1.9	2
1073	Spontaneous suprachoroidal haemorrhage in haemophilia coincident with ChAdOx1 nCoV-19 vaccine. European Journal of Ophthalmology, 2022, , 112067212210982.	0.7	2
1074	Willingness to receive COVID-19 vaccination in people living with HIV/AIDS from Latin America. International Journal of STD and AIDS, 2022, 33, 652-659.	0.5	6
1075	The Impact of <scp>COVID</scp> â€19 Vaccinations on Emergency Department Presentations. EMA - Emergency Medicine Australasia, 2022, , .	0.5	0
1076	Victorian Specialist Immunisation Services (VicSIS) – bolstering adult clinics for COVID-19 vaccines. Human Vaccines and Immunotherapeutics, 2022, 18, 1-6.	1.4	1
1077	Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2. Vaccines, 2022, 10, 649.	2.1	6
1078	Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective. Current Vascular Pharmacology, 2022, 20, 333-340.	0.8	1
1079	Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis. Journal of Cardiovascular Development and Disease, 2022, 9, 150.	0.8	16
1080	Cerebral Venous Thrombosis without Thrombocytopenia after COVID-19 Vaccination. Journal of the Korean Neurological Association, 2022, 40, 160-163.	0.0	1
1081	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. Mucosal Immunology, 2022, 15, 584-594.	2.7	41

#	Article	IF	CITATIONS
1082	Cytoskeleton Dependent Mobility Dynamics of FcÎ ³ RIIA Facilitates Platelet Haptotaxis and Capture of Opsonized Bacteria. Cells, 2022, 11, 1615.	1.8	3
1083	An Integrated Approach on the Diagnosis of Cerebral Veins and Dural Sinuses Thrombosis (a Narrative) Tj ETQq1 1	0.78431 1.7	4ggBT /Ov€
1084	Serum levels of anti-PF4 lgG after AZD1222 (ChAdOx1 nCoV-19) vaccination. Scientific Reports, 2022, 12, 7961.	1.6	7
1085	Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood, 2022, 140, 73-77.	0.6	32
1087	COVID-19 and Autoimmune Liver Diseases. Journal of Clinical Medicine, 2022, 11, 2681.	1.0	13
1088	A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. Viruses, 2022, 14, 969.	1.5	45
1089	Arterial thrombosis following first-dose ChAdOx1 vaccination: a case series. BMJ Neurology Open, 2022, 4, e000270.	0.7	1
1090	The International Society of Pharmacovigilance Vaccines Special Interest Group: Challenges and Opportunities. Drug Safety, 2022, 45, 597-599.	1.4	2
1091	Impact of the COVID-19 Pandemic on the Work Activity of Spanish Physical Therapists and Their Response to Vaccination. Frontiers in Public Health, 2022, 10, .	1.3	0
1092	Thromboembolism after COVID-19 Vaccination: A Systematic Review of Such Events in 286 Patients. Annals of Vascular Surgery, 2022, 84, 12-20.e1.	0.4	17
1093	Ischemic Stroke and Vaccine-Induced Immune Thrombotic Thrombocytopenia following COVID-19 Vaccine: A Case Report with Systematic Review of the Literature. Cerebrovascular Diseases, 2022, 51, 722-734.	0.8	13
1094	COVID-19 vaccination in pregnancy. American Journal of Obstetrics and Gynecology, 2022, 227, 136-147.	0.7	35
1095	Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports. Journal of Medical Case Reports, 2022, 16, 182.	0.4	3
1097	Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. New England Journal of Medicine, 2022, 386, 2084-2096.	13.9	118
1098	Safety profile of COVID-19 vaccines, preventive strategies and patient management. Expert Review of Vaccines, 2022, , 1-9.	2.0	0
1099	New-Onset Acute Kidney Disease Post COVID-19 Vaccination. Vaccines, 2022, 10, 742.	2.1	12
1100	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
1101	Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling. Vaccines, 2022, 10, 715.	2.1	1

#	ARTICLE Increment of D-dimer Associated with Immune Thrombotic Thrombocytopenia in ChAdOx1 nCoV-19	IF	CITATIONS
1102	(AstraZeneca-Oxford) Vaccinated Individuals: A Systematic Review. Archives of Medical Research, 2022,	1.5	1
1103	Post COVID-19 Vaccination Acute Disseminated Encephalomyelitis: A Case Report. Current Medical Imaging, 2023, 19, 91-95.	0.4	5
1104	Thrombosis, cancer, and COVID-19. Supportive Care in Cancer, 2022, 30, 8491-8500.	1.0	10
1105	National safety surveillance of quadrivalent recombinant influenza vaccine in Taiwan during NH 20/21. Vaccine, 2022, , .	1.7	Ο
1106	Methodological Issues in Using a Common Data Model of COVID-19 Vaccine Uptake and Important Adverse Events of Interest: Feasibility Study of Data and Connectivity COVID-19 Vaccines Pharmacovigilance in the United Kingdom. JMIR Formative Research, 2022, 6, e37821.	0.7	4
1107	Concomitant myocarditis and painless thyroiditis after AstraZeneca coronavirus disease 2019 vaccination: a case report. Journal of Medical Case Reports, 2022, 16, 212.	0.4	3
1108	<scp>Antiâ€severe acute respiratory syndrome coronavirusâ€2</scp> adenoviralâ€vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers. British Journal of Haematology, 2022, 198, 257-266.	1.2	12
1109	Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway. European Heart Journal Open, 2022, 2, .	0.9	8
1110	Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature. Frontiers in Medicine, 2022, 9, .	1.2	3
1111	At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant. Frontiers in Immunology, 2022, 13, .	2.2	11
1112	Cardiovascular and Hematologic Complications of COVID-19 Vaccines. Cardiology in Review, 2022, Publish Ahead of Print, .	0.6	2
1113	Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine. BMJ Case Reports, 2022, 15, e246770.	0.2	3
1114	Vaccine-induced immune thrombocytopaenia and thrombosis (VITT) after COVID-19 vaccination. BMJ Case Reports, 2022, 15, e247346.	0.2	3
1115	Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 2022, 31, 974-984.	0.8	13
1116	Human Identical Sequences, hyaluronan, and hymecromone ─ the newÂmechanism and management of COVID-19. Molecular Biomedicine, 2022, 3, 15.	1.7	4
1117	Retinal vascular occlusion and SARS-CoV-2 vaccination. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 3455-3464.	1.0	13
1118	Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer. Thrombosis Research, 2022, 213, S77-S83.	0.8	1
1119	Thrombotic Complications after COVID-19 Vaccination: Diagnosis and Treatment Options. Biomedicines, 2022, 10, 1246.	1.4	7

#	Article	IF	CITATIONS
1120	Assessment of Knowledge about Traditional Medicine Reveals Overuse as a Potential Risk for Aggravating COVID-19 and Underlying Diseases in Geriatrics and Women's Health in the Saudi Population. Clinics and Practice, 2022, 12, 363-373.	0.6	1
1121	Platelet and extracellular vesicles in COVID-19 infection and its vaccines. Transfusion and Apheresis Science, 2022, 61, 103459.	0.5	7
1122	A Case Report of DVT following the Johnson and Johnson Vaccine against the Novel SARS-CoV-2. Case Reports in Infectious Diseases, 2022, 2022, 1-3.	0.2	1
1123	Immune-mediated adverse events post-COVID vaccination and types of vaccines: a systematic review and meta-analysis. The Egyptian Journal of Internal Medicine, 2022, 34, .	0.3	6
1124	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS Medicine, 2022, 19, e1003953.	3.9	27
1125	Acquired hemophilia A after vaccination against SARS-CoV-2 with the mRNA-1273 (Moderna) vaccine. Baylor University Medical Center Proceedings, 2022, 35, 683-685.	0.2	4
1126	Vaccine-induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCoV-19) vaccine: report of two cases. , 2022, 1, .		0
1127	Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database. Vaccines, 2022, 10, 799.	2.1	13
1128	Thrombosis with Thrombocytopenia Syndrome after ChAdOx1 nCoV-19 vaccination. Clinical Neurology, 2022, 62, 487-491.	0.0	1
1129	Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review. , 2022, 10, 251513552210975.	1.4	6
1130	Perceptions and experiences of COVID-19 vaccines' side effects among healthcare workers at an Egyptian University Hospital: a cross-sectional study. Tropical Medicine and Health, 2022, 50, .	1.0	13
1131	mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	160
1132	The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Advances, 2022, 6, 4228-4235.	2.5	18
1133	Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19. Medicina Intensiva (English) Tj ETQq1 1	0.784314 0.1	rgβT /Over
1134	Treatment of drug-induced immune thrombocytopenias. Haematologica, 2022, 107, 1264-1277.	1.7	17
1135	Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. Journal of Molecular Medicine, 2022, 100, 875-901.	1.7	8
1136	Detection of Platelet-Activating Antibodies Associated with Vaccine-Induced Thrombotic Thrombocytopenia by Flow Cytometry: An Italian Experience. Viruses, 2022, 14, 1133.	1.5	3
1137	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. Medical Review, 2022, 2, 169-196.	0.3	5

#	Article	IF	CITATIONS
1138	Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study. BMC Infectious Diseases, 2022, 22, .	1.3	9
1139	Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity. Clinical Microbiology and Infection, 2022, 28, 1390.e1-1390.e7.	2.8	13
1140	Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine. BMJ Case Reports, 2022, 15, e247493.	0.2	4
1141	Antiâ€PF4 testing for vaccineâ€induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. Journal of Thrombosis and Haemostasis, 2022, 20, 1875-1879.	1.9	6
1143	COVID-19 AdenoviralVector Vaccine and Central Retinal Vein Occlusion. Ocular Immunology and Inflammation, 0, , 1-3.	1.0	13
1144	Vaccine-induced immune thrombotic thrombocytopenia is mediated by a stereotyped clonotypic antibody. Blood, 2022, 140, 1738-1742.	0.6	29
1146	Myoglobinuria-induced acute kidney injury secondary to Covishield TM vaccination. Indian Journal of Nephrology, 2022, .	0.2	1
1147	Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal. SAGE Open Medical Case Reports, 2022, 10, 2050313X2211008.	0.2	2
1148	Covid-19 disease and SARS-COV-2 vaccines: the balance between risks and benefits. Buletinul AŞM: Ştiinţe Medicale, 2022, 72, 110-113.	0.0	0
1149	Thrombotic thrombocytopenia After Sinopharm BBIBP orV COVIDâ€19 vaccination. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12750.	1.0	15
1150	Acute Myocardial Infarction After COVID-19 Vaccination: A Case Report. Cureus, 2022, , .	0.2	2
1151	Case report: Pituitary apoplexy after COVID-19 vaccination. Medicina ClÃnica (English Edition), 2022, 158, 498-499.	0.1	7
1152	Systematic Review on Pathophysiological Complications in Severe COVID-19 among the Non-Vaccinated and Vaccinated Population. Vaccines, 2022, 10, 985.	2.1	11
1153	The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood, 2022, 139, 3430-3438.	0.6	19
1154	Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil. Vaccine, 2022, 40, 4788-4795.	1.7	12
1155	A Puzzling Diagnosis of Cerebral Vein Thrombosis in a COVID-19-Vaccinated Patient. Cureus, 2022, , .	0.2	Ο
1156	Non-Arteritic Anterior Ischemic Optic Neuropathy Following COVID-19 Vaccination. Vaccines, 2022, 10, 931.	2.1	8
1157	Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. Radiology, 2022, 305, 590-596.	3.6	3

~		_	
CITAT	ON		DT
CHAD		NLFU	IC I

#	Article	IF	CITATIONS
1158	Acute necrotic disorder of the small intestine post oronavirus diseaseâ€2019 vaccination. DEN Open, 2023, 3, .	0.5	0
1159	Acute limb ischemia secondary to vaccine-induced inmune thrombotic thrombocytopenia (VITT) after ChAdOx1 nCoV-19. Annals of Vascular Surgery Brief Reports and Innovations, 2022, 2, 100102.	0.1	1
1160	COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the "Spike effect". European Journal of Internal Medicine, 2022, 103, 23-28.	1.0	32
1161	Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-Match. Journal of Human Lactation, 2022, 38, 401-406.	0.8	2
1162	Vision-Threatening Ocular Adverse Events after Vaccination against Coronavirus Disease 2019. Journal of Clinical Medicine, 2022, 11, 3318.	1.0	14
1163	Immune Response to SARS-CoV-2 Vaccines. Biomedicines, 2022, 10, 1464.	1.4	24
1164	Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. Scientific Reports, 2022, 12, .	1.6	13
1165	MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature. Journal of Neurology, 2022, 269, 5198-5212.	1.8	32
1166	Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Lancet HIV,the, 2022, 9, e474-e485.	2.1	48
1167	LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination. Neurological Research and Practice, 2022, 4, .	1.0	2
1168	Emerging Pathogens: Novel and Well-Known Infectious Threats in Transfusion Medicine. Transfusion Medicine and Hemotherapy, 0, , 1-2.	0.7	0
1169	Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries. JAMA Network Open, 2022, 5, e2217375.	2.8	20
1170	A Case of ST Segment Elevation Myocardial Infarction Within 24 h of a Third Dose of COVID-19 mRNA Vaccine. Cardiovascular Revascularization Medicine, 2023, 53, S313-S316.	0.3	2
1171	Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services. Clinical Infectious Diseases, 2022, 75, S11-S17.	2.9	8
1172	Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports. Frontiers in Pharmacology, 0, 13, .	1.6	12
1173	A probable case of vaccine-induced immune thrombotic thrombocytopenia secondary to Pfizer Comirnaty COVID-19 vaccine. Journal of the Royal College of Physicians of Edinburgh, The, 2022, 52, 113-116.	0.2	5
1174	COVID-19 Vaccines and Autoimmune Hematologic Disorders. Vaccines, 2022, 10, 961.	2.1	23
1175	Characterization of nanoparticles-based vaccines for COVID-19. Nature Nanotechnology, 2022, 17, 570-576.	15.6	64

		CITATION RE	EPORT	
#	Article		IF	CITATIONS
1177	COVID-19 vaccine-induced thrombotic thrombocytopenia. Canadian Family Physician, 2	2022, 68, 434-437.	0.1	1
1178	Signaling COVID-19 Vaccine Adverse Events. Drug Safety, 2022, 45, 765-780.		1.4	16
1179	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standar with key considerations for a risk/benefit assessment. Vaccine, 2022, 40, 5248-5262.	dized template	1.7	9
1180	Meaningful use of imaging resources to rule out cerebral venous sinus thrombosis afte COVID-19 vaccination: Evaluation of the AHA diagnostic algorithm with a clinical cohor systematic data review. Journal of Clinical Neuroscience, 2022, 102, 5-12.		0.8	1
1181	Towards robust immune responses after heterologous COVID-19 vaccination and its ap perspectives. , 2022, 1, 20220008.	plication		1
1182	Biopharmaceuticals for prevention of COVID-19: A scoping review. Asian Pacific Journal Medicine, 2022, 15, 245.	of Tropical	0.4	2
1183	Recurrent Coronary Artery Thrombosis on Triple Anti-Thrombotic Therapy, Is There a Po Association with ChAdOx1 nCoV-19 Vaccination?. Case Reports in Clinical Medicine, 20		0.1	0
1184	Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta Dominance. SSRN Journal, 0, , .	Electronic	0.4	0
1185	COVID-19 WAR: Controversial Guidelines. Journal of Internal Medicine and Emergency I	Research, 0, , .	0.0	0
1186	The Frequency and Patterns of Post-COVID-19 Vaccination Syndrome Reveal Initially M Potentially Immunocytopenic Signs in Primarily Young Saudi Women. Vaccines, 2022, 1		2.1	3
1187	Commentary on "Risk of venous thromboembolism after COVIDâ€19 vaccinationâ€ and Haemostasis, 2022, 20, 1562-1564.	Journal of Thrombosis	1.9	0
1188	COVID-19 vaccine-induced immune thrombotic thrombocytopenia. Atherothrombosis,	2022, 12, 114-126.	0.1	0
1189	Comparison of COVID-19 Vaccines Introduced in Korea. Biomedical Science Letters, 20	22, 28, 67-82.	0.0	1
1190	SARS-CoV-2 Infection in Patients with a History of VITT. New England Journal of Medicir 88-90.	ne, 2022, 387,	13.9	7
1191	Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Saf Side Effects. Pathogens, 2022, 11, 743.	ety and Putative	1.2	11
1192	COVID-19 Vaccine Hesitancy: The Perils of Peddling Science by Social Media and the La 2022, 10, 1059.	y Press. Vaccines,	2.1	6
1193	Pulmonary embolism with junctional tachycardia: A serious complication after COVID-1 Annals of Medicine and Surgery, 2022, 80, .	9 vaccination.	0.5	2
1195	Understanding the Correlation of Diet, Immunity, and Probiotics: A Credible Implication Infections. Biosciences, Biotechnology Research Asia, 2022, 19, 373-385.	in SARS-CoV2	0.2	0

\sim		<u>_</u>	
		Repo	DT
\sim	IIAI	KLPU	ALC L

#	Article	IF	CITATIONS
1196	A Resected Case of Lung Cancer with Pulmonary Thromboembolism After COVID-19 Vaccination. Japanese Journal of Lung Cancer, 2022, 62, 235-241.	0.0	1
1197	Immunogenicity and efficacy of Ad26. <scp>COV2</scp> .S: An adenoviral vector–based <scp>COVID</scp> â€19 vaccine. Immunological Reviews, 2022, 310, 47-60.	2.8	10
1198	Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins. Viruses, 2022, 14, 1415.	1.5	39
1199	Special Issue "COVID-19 and Venous Thromboembolism― Journal of Clinical Medicine, 2022, 11, 3822.	1.0	0
1200	Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine. ELife, 0, 11, .	2.8	23
1201	Evans Syndrome Presenting as an Atypical Complication of SARS-CoV-2 Vaccination. Cureus, 2022, , .	0.2	1
1202	Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms, 2022, 10, 1450.	1.6	28
1203	Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study. BMJ, The, 0, , e070483.	3.0	7
1204	Kidney Transplantation From Deceased Donors With Vaccine-induced Immune Thrombocytopenia and Thrombosis: An Updated Analysis of the UK Experience. Transplantation, O, Publish Ahead of Print, .	0.5	0
1205	Monocyte-derived alveolar macrophages autonomously determine severe outcome of respiratory viral infection. Science Immunology, 2022, 7, .	5.6	39
1206	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. ELife, 0, 11, .	2.8	7
1207	Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers. Frontiers in Immunology, 0, 13, .	2.2	11
1208	Transjugular intrahepatic portosystemic shunt, local thrombaspiration, and lysis for management of fulminant portomesenteric thrombosis and atraumatic splenic rupture due to vector-vaccine-induced thrombotic thrombocytopenia: a case report. Journal of Medical Case Reports, 2022, 16, .	0.4	1
1209	Venous Thromboembolism in Sepsis: From Bench to Bedside. Biomedicines, 2022, 10, 1651.	1.4	5
1210	Pulmonary embolism and inferior vena cava thrombosis in a young male patient after mRNA-1273 (Moderna) immunization: A case report. Tuberculosis and Respiratory Diseases, 0, , .	0.7	1
1211	<scp>AstraZeneca COVID</scp> â€19 vaccine: A possible risk factor for ischemic stroke and cerebral venous sagittal sinus thrombosis: A case series. Clinical Case Reports (discontinued), 2022, 10, .	0.2	3
1212	The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans. Therapie, 2023, 78, 293-302.	0.6	1
1213	Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review. World Journal of Experimental Medicine, 2022, 12, 53-67.	0.9	12

#	ARTICLE Immune Thrombocytopenia in Previously Healthy Individuals Following SARS-CoV-2 Vaccination	IF	CITATIONS
1214	(COVID-19 Immunization): A Descriptivé Research of 70 Instances With a Focus on Biomarkers, Predictive Outcomes, and Consequences. Cureus, 2022, , .	0.2	2
1215	Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis. Npj Vaccines, 2022, 7, .	2.9	2
1216	Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series. The Lancet Healthy Longevity, 2022, 3, e491-e500.	2.0	24
1217	Retrospective review COVID-19 vaccine induced thrombotic thrombocytopenia and cerebral venous thrombosis-what can we learn from the immune response. Clinical Imaging, 2022, 90, 63-70.	0.8	5
1218	Management of Cerebral Venous Thrombosis Due to Adenoviral <scp>COVID</scp> â€19 Vaccination. Annals of Neurology, 2022, 92, 562-573.	2.8	21
1219	Acute lower limb ischemia caused by vaccine-induced immune thrombotic thrombocytopenia: focus on perioperative considerations for 2 cases. Thrombosis Journal, 2022, 20, .	0.9	1
1220	The use of viral vectors in vaccine development. Npj Vaccines, 2022, 7, .	2.9	73
1221	Vaccine-induced immune thrombotic thrombocytopenia presenting as a mimic of heparin-induced thrombocytopenia in a hemodialysis patient receiving ChAdOx1 nCoV-19 vaccine. Renal Failure, 2022, 44, 1131-1134.	0.8	3
1222	Keeping up with the COVID's—Could siRNAâ€based antivirals be a part of the answer?. Exploration, 2022, 2, .	5.4	7
1223	SARS-CoV-2 Vaccination-Induced Thrombotic Thrombocytopenia: A Rare but Serious Immunologic Complication. Annual Review of Medicine, 2023, 74, 65-74.	5.0	8
1224	Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study. EClinicalMedicine, 2022, 50, 101504.	3.2	28
1225	Brain dural arteriovenous fistulas in the COVID-19 Era: A warning and rationale for association. Clinical Neurology and Neurosurgery, 2022, 220, 107367.	0.6	1
1226	Risk of gout flares after COVID-19 vaccination: A case-crossover study. Seminars in Arthritis and Rheumatism, 2022, 56, 152059.	1.6	4
1227	Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review. Infectious Disease Reports, 2022, 14, 537-546.	1.5	23
1228	Severe Thrombocytopenia Two Weeks Following Immunization with the Janssen Ad26.CoV2.S Vaccine. Case Reports in Hematology, 2022, 2022, 1-4.	0.3	1
1230	A Case of COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia. Cureus, 2022, , .	0.2	1
1231	Cerebral venous sinus thrombosis after COVID-19 vaccination and congenital deficiency of coagulation factors: Is there a correlation?. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	4
1232	Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. Lancet Microbe, The, 2022, 3, e663-e671.	3.4	12

#	Article	IF	CITATIONS
1235	Acquired Thrombotic Thrombocytopenic Purpura After ChAdOx1 nCoV-19 Vaccine: A Case Report. , 2022, 1, .		0
1238	Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations. Vaccine, 2022, 40, 5585-5593.	1.7	3
1239	Clinical characteristics of patients with COVID-19 vaccine-related pneumonitis: a case series and literature review. Korean Journal of Internal Medicine, 0, , .	0.7	2
1241	Four cases of cytokine storm after COVID-19 vaccination: Case report. Frontiers in Immunology, 0, 13, .	2.2	15
1242	Changes in thrombosis-related parameters after AstraZeneca COVID-19 vaccination in a male volunteer: a case report. Journal of Medical Case Reports, 2022, 16, .	0.4	3
1243	Trends in reporting embolic and thrombotic events after COVID-19 vaccination: A retrospective, pharmacovigilance study. PLoS ONE, 2022, 17, e0269268.	1.1	3
1244	Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis (CVST): a case report from Malaysia. Blood Research, 2022, , .	0.5	1
1245	Unprovoked Submassive Saddle Pulmonary Embolism in an Adult Male After Pfizer COVID-19 Vaccination. Cureus, 2022, , .	0.2	0
1246	Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2022, 380, .	1.6	7
1247	Possible COVID-19 MRNA Vaccine-Induced Case of Unilateral Central Retinal Vein Occlusion. Ocular Immunology and Inflammation, 2023, 31, 1145-1150.	1.0	9
1248	Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nature Communications, 2022, 13, .	5.8	14
1249	Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nature Communications, 2022, 13, .	5.8	33
1250	New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatology International, 2022, 42, 2267-2276.	1.5	22
1251	Vaccines platforms and COVID-19: what you need to know. Tropical Diseases, Travel Medicine and Vaccines, 2022, 8, .	0.9	16
1252	Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data. Drug Safety, 2022, 45, 1003-1008.	1.4	4
1253	Multisystem Inflammatory Syndrome in Adults (MIS-A) After COVID-19 Infection and Recent Vaccination with Recombinant Adenoviral Vector Encoding the Spike Protein Antigen of SARS-CoV-2 (ChAdOx1) Tj ETQq1 1 0	.7 84 314 rg	g&T /Overlo
1254	Elevated NETs and Calprotectin Levels after ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects. Vaccines, 2022, 10, 1267.	2.1	5
1255	B-cell-guided strategy for SARS-CoV2 vaccination after autologous stem cell transplantation for B-cell lymphoma $\hat{a} \in \mathbb{C}^{n}$ a case report. Annals of Hematology, 0, , .	0.8	1

		CITATION R	EPORT	
#	Article		IF	Citations
1256	Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia. Viruses, 20	022, 14, 1702.	1.5	7
1257	A 54-Year-Old Man With Migratory Pulmonary Consolidation and Progressive Dyspnea. e85-e88.	Chest, 2022, 162,	0.4	0
1258	Reactivation of adult-onset Still's disease after use of the COVID-19 ChAdOx1-S va Reports, 2022, 15, e249290.	ccine. BMJ Case	0.2	6
1259	Kidney transplantation from deceased donors with vaccineâ€induced thrombosis and t (VITT): Definitely feasible and safe?. Transplant Infectious Disease, 2022, 24, .	hrombocytopenia	0.7	1
1261	Quantitative interpretation of PF4/heparinâ€EIA optical densities in predicting plateleta antibodies. Journal of Thrombosis and Haemostasis, 2022, 20, 2579-2586.	à€ectivating VITT	1.9	12
1262	Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross- section Northwest Ethiopia. Human Vaccines and Immunotherapeutics, 2022, 18, .	al survey in	1.4	3
1263	Decompressive craniectomy for intracranial hypertension in vaccine-induced immune the thrombocytopaenia: a case series. British Journal of Neurosurgery, 0, , 1-4.	hrombotic	0.4	0
1264	Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case updated literature review. Journal of Autoimmunity, 2022, 132, 102898.	reports and	3.0	44
1265	Potential mechanisms of vaccine-induced thrombosis. European Journal of Internal Mec 105, 1-7.	licine, 2022,	1.0	9
1266	The current status of COVID-19 vaccines. A scoping review. Drug Discovery Today, 202	2, 27, 103336.	3.2	7
1267	Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse benefits outweigh the risks. Expert Review of Vaccines, 2022, 21, 1377-1394.	effects;	2.0	8
1268	Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies<!--</td--><td>b>. Blood, 0, , .</td><td>0.6</td><td>7</td>	b>. Blood, 0, , .	0.6	7
1269	Ventricular tachycardia because of myocardial infarction after <scp>COVID</scp> â€19 Journal of Arrhythmia, 2022, 38, 824-826.	vaccination.	0.5	2
1270	Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: Review. Medicines (Basel, Switzerland), 2022, 9, 43.	A Systematic	0.7	4
1271	COVID-19 vaccine (Ad26.COV2.S), an unlikely culprit of portal vein thrombosis in a mic Thrombosis Update, 2022, 8, 100119.	ldle-aged man.	0.4	0
1272	Preexisting anti-PF4 antibodies are not further triggered upon vaccination with SARS-C vaccines in a cohort of 400 health care workers. Thrombosis Research, 2022, 218, 142	oV-2 vector -144.	0.8	0
1273	Endovascular mechanical thrombectomy for cerebral venous sinus thrombosis after m SIRS-CoV-2 vaccination. Interdisciplinary Neurosurgery: Advanced Techniques and Case 2022, 30, 101644.		0.2	5
1275	Case reports of management of aplastic anemia after COVID-19 vaccination: a single ir experience in Taiwan. International Journal of Hematology, 2023, 117, 149-152.	istitute	0.7	7

#	Article	IF	Citations
1277	Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase. Stroke, 2022, 53, 3206-3210.	1.0	12
1278	Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule Immunology Letters, 2022, 250, 1-6.	1.1	3
1279	A systemic review and recommendation for an autopsy approach to death followed the COVID 19 vaccination. Forensic Science International, 2022, 340, 111469.	1.3	1
1280	Autopsy findings of post-COVID-19 vaccination deaths in Tokyo Metropolis, Japan, 2021. Legal Medicine, 2022, 59, 102134.	0.6	8
1281	Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?. International Journal of Infectious Diseases, 2022, 124, 1-10.	1.5	12
1282	"COVID-19 associated divergent thrombotic thrombocytopenic purpura (TTP) syndromes reported so far, five and countingâ€ŧ Classification and possible therapeutic options. Thrombosis Research, 2022, 219, 86-88.	0.8	2
1284	Cerebral venous sinus thrombosis-associated hemorrhage in vaccine-induced immune thrombotic thrombocytopenia: Catastrophic outcome if delayed diagnosis and treatment. Formosan Journal of Surgery, 2022, 55, 158.	0.1	1
1285	Absence of Platelet Overactivation and Hypercoagulability Among Patients with Coronary Atherosclerosis Disease after Vaccination Against SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	0
1286	Portal vein thrombosis as a thrombotic complication of COVID-19 mRNA vaccine: A case report and literature review. IDCases, 2022, 29, e01582.	0.4	3
1287	Breast cancer cell-based ELISA: a potential material for better detection of heparin-induced thrombocytopenia antibodies. Journal of Materials Chemistry B, 2022, 10, 7708-7716.	2.9	1
1288	Multiple sites of thrombosis without thrombocytopenia after a second dose of Pfizer-BioNTech COVID-19 vaccine. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211285.	1.0	2
1289	Vaccines for the Elderly. Quality of Life in Asia, 2022, , 83-104.	0.1	0
1290	Vaccine History: From Smallpox to Covid-19. Engineering Materials, 2022, , 519-543.	0.3	0
1291	COVID-19 Vaccine-Induced Thrombotic Thrombocytopaenia With Venous and Arterial Thrombosis: A Case Report. Cureus, 2022, , .	0.2	1
1292	An autopsy case of cerebral arterial thrombosis after vaccination with ChAdOx1 nCOV-19. Journal of Medicine and Life Science, 2022, 19, 74-77.	0.1	0
1293	Vaccine induced thrombotic thrombocytopenia: development and reactivity of anti-platelet factor 4 antibodies and immune pathogenic mechanisms. Exploration of Immunology, 0, , 604-621.	1.7	2
1294	Chop-Chop: The Future of Bacterial Enzymes in Transfusion Medicine. Transfusion Medicine Reviews, 2022, 36, 246-251.	0.9	3
1295	SARS-CoV-2 and extracellular vesicles: An intricate interplay in pathogenesis, diagnosis and treatment. Frontiers in Nanotechnology, 0, 4, .	2.4	3

#	ARTICLE	IF	CITATIONS
1296 1297	Thrombotic Thrombocytopenic Purpura After Ad6.COV2.S Vaccination. Cureus, 2022, , . Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2	0.2	1
1297	Infection: A Humoral and Cellular Investigation. Viruses, 2022, 14, 1916. Atypical acute disseminated encephalomyelitis with systemic inflammation after a first dose of	1.0	4
1299	AztraZaneca COVID-19 vaccine. A case report. Frontiers in Neurology, 0, 13, . Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review. Neuropsychiatric Disease and Treatment, 0, Volume 18, 1907-1916.	1.0	3
1300	Adenoviral vector-based COVID-19 vaccines-associated cerebral venous sinus thromboses: Are those adverse events related to the formation of neutrophil extracellular traps?. Vacunas (English Edition),	0.3	0
1301	2022, 23, S63-S66. Relationship Between Vaccination and Immune Thrombotic Thrombocytopenia: Coincidental or Causal?. Cureus, 2022, , .	0.2	1
1302	Vaccination and Mortality of Patients with a Novel Coronavirus Infection (COVID-19): A Global Approach. Russian Journal of Gastroenterology Hepatology Coloproctology, 2022, 32, 23-28.	0.2	0
1303	Case Report: Adult Onset Still's Disease after vaccination against Covid-19. Wellcome Open Research, 0, 6, 333.	0.9	2
1304	Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Herald of the Russian Academy of Sciences, 2022, 92, 398-403.	0.2	7
1305	SARS CoV- 2 vaccination induces antibodies against cardiolipin. BMC Research Notes, 2022, 15, .	0.6	6
1306	Central retinal vein occlusion following mRNA severe acute respiratory syndrome coronavirus 2 vaccination. International Journal of Case Reports and Images, 2022, 13, 105-107.	0.0	1
1307	Neurological Complications of SARS-CoV-2 Infection and COVID-19 Vaccines: From Molecular Mechanisms to Clinical Manifestations. Current Drug Targets, 2022, 23, .	1.0	1
1308	New insights into human immune memory from <scp>SARS oV</scp> â€2 infection and vaccination. Allergy: European Journal of Allergy and Clinical Immunology, 0, , .	2.7	5
1310	Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis. PLoS ONE, 2022, 17, e0273676.	1.1	5
1311	NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia. Nature Communications, 2022, 13, .	5.8	36
1312	Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine. BMJ Case Reports, 2022, 15, e249477.	0.2	1
1313	Rapid progressive vaccine-induced immune thrombotic thrombocytopenia with cerebral venous thrombosis after ChAdOx1 nCoV-19 (AZD1222) vaccination: A case report. World Journal of Clinical Cases, 2022, 10, 9462-9469.	0.3	2
1314	Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2022, 40, 6431-6444.	1.7	2

#	Article	IF	CITATIONS
1315	Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
1316	<scp>COVID</scp> â€19 vaccineâ€associated myositis – a case report. Clinical Case Reports (discontinued), 2022, 10, .	0.2	3
1317	Information systems for vaccine safety surveillance. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	5
1318	Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares. RMD Open, 2022, 8, e002460.	1.8	8
1320	<scp>COVID</scp> â€19: Vaccineâ€induced immune thrombotic thrombocytopenia. European Journal of Haematology, 2022, 109, 619-632.	1.1	3
1321	Predictors of vaccine hesitancy among disability support workers in Australia: A cross-sectional survey. Disability and Health Journal, 2022, , 101369.	1.6	1
1322	Vaccine-induced immune thrombotic thrombocytopenia. Best Practice and Research in Clinical Haematology, 2022, , 101381.	0.7	6
1323	A Case of Hemophagocytic Lymphohistiocytosis following Second Dose of COVID-19 Vaccination. Acta Haematologica, 2023, 146, 68-74.	0.7	6
1324	COVID vaccine-induced immune thrombotic thrombocytopenia: Rare but relevant. European Journal of Internal Medicine, 2022, 105, 20-22.	1.0	1
1325	Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea. Journal of Microbiology, Immunology and Infection, 2022, 55, 1013-1024.	1.5	6
1326	Sinopharm's BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2. Vaccines, 2022, 10, 1462.	2.1	5
1327	Thrombosis of the deep dorsal vein of the penis caused by vaccine-induced thrombotic thrombocytopenia: First reported case. Arab Journal of Urology Arab Association of Urology, 0, , 1-4.	0.7	1
1328	Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. Npj Vaccines, 2022, 7, .	2.9	3
1329	Case report: An unusual case of multisite embolism in a patient with adenovirus pneumoniae. Frontiers in Medicine, 0, 9, .	1.2	0
1331	COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness. Viruses, 2022, 14, 2086.	1.5	12
1332	Assessment of immunological antiâ€platelet factor 4 antibodies for vaccineâ€induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients. Journal of Thrombosis and Haemostasis, 2022, 20, 2896-2908.	1.9	20
1333	The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors. Frontiers in Immunology, 0, 13, .	2.2	5
1334	Portal Vein Thrombosis After Second Pfizer/BioNTech COVID-19 Vaccine. Journal of Vascular Surgery Cases and Innovative Techniques, 2022, , .	0.3	1

#	Article	IF	CITATIONS
1335	Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies. International Journal of Molecular Sciences, 2022, 23, 11500.	1.8	6
1336	Influenza vaccination features revealed by a singleâ€cell transcriptome atlas. Journal of Medical Virology, 2023, 95, .	2.5	5
1337	mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study. Drug Safety, 2022, 45, 1477-1490.	1.4	11
1339	Thrombotic thrombocytopenic purpura after vaccination for COVID-19: lesson for the clinical nephrologist. Journal of Nephrology, 0, , .	0.9	1
1340	Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. Frontiers in Medicine, 0, 9, .	1.2	17
1341	Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report. Thrombosis Journal, 2022, 20, .	0.9	6
1342	Mechanical prosthetic valve thrombosis after ChAdOx1-nCoV-19 vaccination: A case report. IHJ Cardiovascular Case Reports (CVCR), 2022, , .	0.0	0
1344	Case report: Vaccine-induced immune thrombotic thrombocytopenia complicated by acute cerebral venous thrombosis and hemorrhage after AstraZeneca vaccines followed by Moderna COVID-19 vaccine booster and surgery. Frontiers in Neurology, 0, 13, .	1.1	3
1345	â€~Mix and Match' vaccination: Is dengue next?. Vaccine, 2022, 40, 6455-6462.	1.7	0
1347	Case report: Reactive Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis and thrombosis with thrombocytopenia syndrome following SARS-CoV-2 vaccination and treated with intravenous immunoglobulin. , 0, 1, .		0
1348	Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia. Infection, 2023, 51, 231-238.	2.3	2
1349	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. EBioMedicine, 2022, 85, 104294.	2.7	11
1350	Ocular adverse effects of COVID-19 vaccines: A systematic review. Journal of Family Medicine and Primary Care, 2022, 11, 5041.	0.3	4
1351	COVID-19 vaccination and immune thrombocytopenia. Japanese Journal of Thrombosis and Hemostasis, 2022, 33, 576-579.	0.1	0
1352	Uncertainty in Medicine: An Active Definition. Future of Business and Finance, 2022, , 329-341.	0.3	1
1353	An unusual case of superior vena cava syndrome. Clinical Medicine, 2022, 22, 54-55.	0.8	1
1354	Ocular effects caused by viral infections and corresponding vaccines: An overview of varicella zoster virus, measles virus, influenza viruses, hepatitis B virus, and SARS-CoV-2. Frontiers in Medicine, 0, 9, .	1.2	3
1355	Dangerous B-cell clones. Blood, 2022, 140, 1663-1665.	0.6	1

#	Article	IF	CITATIONS
1356	Cellular and Humoral SARS-CoV-2 Vaccination Responses in 192 Adult Recipients of Allogeneic Hematopoietic Cell Transplantation. Vaccines, 2022, 10, 1782.	2.1	4
1357	Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. EBioMedicine, 2022, 85, 104298.	2.7	70
1358	Temporal Association between Hampton's Hump Pulmonary Embolism and First-Dose ChAdOx1 nCov-19 Vaccine in a Patient with Activated Protein C Resistance. Vaccines, 2022, 10, 1659.	2.1	0
1359	Central retinal vein occlusion post ChAdOx1 nCoV-19 vaccination – can it be explained by the two-hit hypothesis?. Journal of Ophthalmic Inflammation and Infection, 2022, 12, .	1.2	3
1360	Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ, The, 0, , e071594.	3.0	26
1361	SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders. Applied Biochemistry and Biotechnology, 2023, 195, 1541-1573.	1.4	4
1362	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. Journal of Biomedical Science, 2022, 29, .	2.6	77
1363	Factor V Leiden mutation detection before AstraZeneca vaccine. Italian Journal of Vascular and Endovascular Surgery, 2022, 29, .	1.0	1
1364	Safety of COVID-19 mRNA vaccination in patients with history of acquired hemophilia A: a case series. , 2022, 1, .		0
1365	Silent progressive bilateral papillitis after COVID-19 vaccination: A case report. Medicine (United) Tj ETQq1 1 0.7	84314 rgE 0.4	BT /Overlock
1366	Comparative risk of cerebral venous sinus thrombosis (CVST) following COVID-19 vaccination or infection: A national cohort study using linked electronic health records. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	4
1367	Vaccine-induced immune thrombotic thrombocytopenia: Updates in pathobiology and diagnosis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
1368	Do we miss rare adverse events induced by COVID-19 vaccination?. Frontiers in Medicine, 0, 9, .	1.2	8
1369	Chemokines Effective on Platelet Functions. Biochemistry, 0, , .	0.8	0
1370	Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on. Frontiers in Public Health, 0, 10, .	1.3	3
1371	Corona virus disease-19 vaccine–associated autoimmune disorders. Rheumatology and Immunology Research, 2022, 3, 111-119.	0.2	1
1372	Serum Proteomic Analysis for New Types of Long-Term Persistent COVID-19 Patients in Wuhan. Microbiology Spectrum, 2022, 10, .	1.2	3
1373	Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial. Nature Medicine, 2022, 28, 2611-2621.	15.2	24

#	Article	IF	CITATIONS
1374	Antiâ€platelet factor 4/heparin antibodies in patients with Hantaan virus infection. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12813.	1.0	1
1375	Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern. International Journal of Molecular Sciences, 2022, 23, 13220.	1.8	5
1377	COVID-19 Vaccine Hesitancy among Pregnant Women Attending Antenatal Clinics in Pakistan: A Multicentric, Prospective, Survey-Based Study. Viruses, 2022, 14, 2344.	1.5	7
1378	New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review. BMC Gastroenterology, 2022, 22, .	0.8	8
1379	Comorbidities, Associated Diseases, and Risk Assessment in COVID-19—A Systematic Review. International Journal of Clinical Practice, 2022, 2022, 1-24.	0.8	17
1380	Postmortem PF4 antibodies confirm a rare case of thrombosis thrombocytopenia syndrome associated with ChAdOx1 nCoV-19 anti-COVID vaccination. International Journal of Legal Medicine, 2023, 137, 487-492.	1.2	2
1381	Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study. BMC Infectious Diseases, 2022, 22, .	1.3	4
1382	To study the effect of â€~Covishield' vaccination on pre-donation platelet counts of plateletpheresis donors. Hematology, Transfusion and Cell Therapy, 2022, , .	0.1	1
1383	Spontaneous Subarachnoid Haemorrhage After COVID-19 Vaccination; a Rare Case Report. Archives of Clinical Infectious Diseases, 2022, 17, .	0.1	0
1384	Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (<scp>SARSâ€CoV</scp> â€2): A followâ€up study. European Journal of Neurology, 2023, 30, 463-473.	1.7	12
1385	SARS oVâ€2â€vaccines and neurologic diseases: Cause or coincidence?. European Journal of Neurology, 0, , .	1.7	0
1386	A systematic review of current status and challenges of vaccinating children against SARS-CoV-2. Journal of Infection and Public Health, 2022, 15, 1212-1224.	1.9	2
1387	Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Science Immunology, 2022, 7, .	5.6	39
1389	Anti-PF4 antibodies associated with disease severity in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	16
1390	Challenges in managing patients on anticoagulation: Thrombocytopenia, resumption after bleeding and recurrent thrombosis. Journal of the Royal College of Physicians of Edinburgh, The, 2022, 52, 341-349.	0.2	1
1391	NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens. Journal of Clinical Virology, 2022, 157, 105321.	1.6	17
1392	Spectrum of Neurological Complications Following COVID-19 Vaccination in India. Journal of Clinical		

#	Article	IF	CITATIONS
1394	Incidence of Cerebral Venous Thrombosis: A Population-Based Study, Systematic Review, and Meta-Analysis. Stroke, 2023, 54, 169-177.	1.0	6
1395	From the Discovery of ADAMTS13 to Current Understanding of Its Role in Health and Disease. Seminars in Thrombosis and Hemostasis, 2023, 49, 284-294.	1.5	5
1396	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. Thrombosis Update, 2022, , 100126.	0.4	0
1397	Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan. Frontiers in Immunology, 0, 13, .	2.2	3
1399	Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS–CoV–2: Prospects for mass scale immunity-screening in large populations. Frontiers in Immunology, 0, 13, .	2.2	1
1400	Myocardial infarction following COVID-19 vaccine administration; a systematic review. Heliyon, 2022, 8, e11385.	1.4	4
1401	Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets, 2023, 34, .	1.1	13
1402	The Burden of Cerebral Venous Thrombosis in a Romanian Population across a 5-Year Period. Life, 2022, 12, 1825.	1.1	1
1403	Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers. Yonsei Medical Journal, 0, 63, .	0.9	5
1405	Portal Vein and Mesenteric Artery Thrombosis Following the Administration of an Ad26.COV2-S Vaccine—First Case from Romania: A Case Report. Vaccines, 2022, 10, 1950.	2.1	3
1406	Case mistaken for leukemia after mRNA COVID-19 vaccine administration: A case report. World Journal of Clinical Cases, 0, 10, 12268-12277.	0.3	2
1407	Incidence and outcomes of splanchnic vein thrombosis after diagnosis of COVID-19 or COVID-19 vaccination: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2023, 55, 18-31.	1.0	4
1408	Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 106860.	0.7	3
1409	Approach to the Patient With Adrenal Hemorrhage. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 995-1006.	1.8	8
1410	A relax-and-fix Pareto-based algorithm for a bi-objective vaccine distribution network considering a mix-and-match strategy in pandemics. Applied Soft Computing Journal, 2023, 132, 109862.	4.1	2
1411	Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study. Vaccine, 2023, 41, 251-262.	1.7	25
1412	COVID-19 Vaccination in Korea: Past, Present, and the Way Forward. Journal of Korean Medical Science, 2022, 37, .	1.1	20
1413	Comparison of COVID-19 Pandemic Waves in 10 Countries in Southern Africa, 2020–2021. Emerging Infectious Diseases, 2022, 28, .	2.0	5

# 1414	ARTICLE COVID-19 in Patients with Hematologic Diseases. Biomedicines, 2022, 10, 3069.	IF 1.4	Citations 3
1415	COVID-19 Vaccine Hesitancy Among Medicare Beneficiaries with and Without Cancer History: A US Population-based Study. Journal of Community Health, 0, , .	1.9	0
1417	Evaluation of the Oral Microcirculation in Patients Undergoing Anti COVID-19 Vaccination: A Preliminary Study. Vaccines, 2022, 10, 1978.	2.1	5
1418	Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology. Vaccines, 2022, 10, 2004.	2.1	17
1419	Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom. Nature Communications, 2022, 13, .	5.8	12
1420	High-frequency Contactless Sensor for the Detection of Heparin-Induced Thrombocytopenia Antibodies via Platelet Aggregation. International Journal of Molecular Sciences, 2022, 23, 14395.	1.8	1
1421	Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain. Nature Communications, 2022, 13, .	5.8	9
1423	Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. Acta Pharmaceutica Sinica B, 2023, 13, 2897-2925.	5.7	1
1424	Seven classes of antiviral agents. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	8
1425	Neurological Complications Following COVID-19 Vaccination. Current Neurology and Neuroscience Reports, 2023, 23, 1-14.	2.0	12
1426	Severe Thrombocytopenia, Thrombosis and Anti-PF4 Antibody after Pfizer-BioNTech COVID-19 mRNA Vaccine Booster—Is It Vaccine-Induced Immune Thrombotic Thrombocytopenia?. Vaccines, 2022, 10, 2023.	2.1	4
1427	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	1.7	2
1428	Coincidental or causal? A case report of acquired thrombotic thrombocytopenic purpura following mRNA-1273 Covid-19 vaccination. Hematology, Transfusion and Cell Therapy, 2022, , .	0.1	3
1429	Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	24
1430	Factors Associated With Vaccine-Induced T-Cell Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Kidney Transplant Recipients. Journal of Infectious Diseases, 0, , .	1.9	4
1431	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions, 2022, 50, 1643-1658.	1.6	6
1432	Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer—COVID Lung Vaccine Study. Cancers, 2023, 15, 137.	1.7	2
1433	Fatal Post COVID mRNA-Vaccine Associated Cerebral Ischemia. Neurohospitalist, The, 0, , 194187442211368.	0.3	2

# 1434	ARTICLE Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence. Nature Communications, 2022, 13, .	IF 5.8	CITATIONS
1435	Therapeutic challenges in COVID-19. Current Molecular Medicine, 2022, 23, .	0.6	0
1436	Safety Monitoring of <scp>COVID</scp> â€19 Vaccines: Perspective from the European Medicines Agency. Clinical Pharmacology and Therapeutics, 2023, 113, 1223-1234.	2.3	12
1437	COVID-19 vaccination and Atypical hemolytic uremic syndrome. Frontiers in Immunology, 0, 13, .	2.2	10
1438	Progress and challenges of mRNA vaccines. , 2023, 1, .		5
1439	Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. Nature Communications, 2022, 13, .	5.8	18
1440	COVID-19 mRNA vaccine: safety and situation of clinical application. , 2022, , .		0
1442	Co-VAN study: COVID-19 vaccine associated neurological diseases- an experience from an apex neurosciences centre and review of the literature. Journal of Clinical Neuroscience, 2023, 108, 37-75.	0.8	4
1443	Thrombosis with thrombocytopenia after vaccination with the ChAdOx1 nCoV-19 vaccine (Oxford–AstraZeneca): implications of gender-specific tissue-factor gene polymorphisms?. Expert Review of Clinical Pharmacology, 0, , 1-3.	1.3	1
1444	Current evidence of COVID-19 vaccination-related cardiovascular events. Postgraduate Medicine, 2023, 135, 102-120.	0.9	5
1445	<scp>COVID</scp> â€19 vaccination coverage and vaccine hesitancy among Australians with disability and longâ€ŧerm health conditions. Health Promotion Journal of Australia, 2023, 34, 895-902.	0.6	2
1446	Comprehensive description of adult-onset Still's disease after COVID-19 vaccination. Journal of Autoimmunity, 2023, 134, 102980.	3.0	4
1447	Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nature Reviews Immunology, 2023, 23, 381-396.	10.6	61
1448	Pasaporte COVID a examen. Nudging y derechos fundamentales. Revista De Derecho Politico, 2022, , 171-204.	0.1	0
1449	Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Frontiers in Immunology, 0, 13, .	2.2	15
1450	Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerging Microbes and Infections, 2023, 12, .	3.0	16
1452	Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2023, 49, 621-633.	1.5	12
1453	A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVIDâ€19 mRNA vaccination. British Journal of Clinical Pharmacology, 0, , .	1.1	4

#	Article	IF	CITATIONS
1454	COVID-19 Vaccine-Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications. Seminars in Thrombosis and Hemostasis, 2023, 49, 009-014.	1.5	8
1456	Acute Vascular Injury in COVID-19. Contemporary Cardiology, 2022, , 151-170.	0.0	0
1457	Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic. BMJ Open, 2023, 13, e063645.	0.8	1
1458	Cardiovascular Complications in Coronavirus Disease 2019—Pathogenesis and Management. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 021-034.	0.8	2
1459	Prevalence of antiâ€platelet factor 4 antibodies in healthy vaccinees with adenoviral vector vaccines—A systematic review and metaâ€analysis. British Journal of Haematology, 0, , .	1.2	0
1460	COVID-19 Vaccination Is Not Associated with Psychiatric Adverse Events: A Meta-Analysis. Vaccines, 2023, 11, 194.	2.1	1
1461	The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine. Viruses, 2023, 15, 204.	1.5	11
1462	Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. Journal of Cardiovascular Pharmacology and Therapeutics, 2023, 28, 107424842211450.	1.0	8
1463	Analysis of spontaneous reports of suspected adverse reactions after vaccination against COVID-19 in Slovakia. Frontiers in Pharmacology, 0, 14, .	1.6	3
1464	A Case of Vaccine-Induced Thrombocytopenic Thrombosis Manifesting as Cerebral Venous Thrombosis and Intracerebral Bleed. Cureus, 2023, , .	0.2	Ο
1465	Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases. Journal of Clinical and Translational Hepatology, 2023, 000, 000-000.	0.7	0
1466	Political legitimacy and vaccine hesitancy: Disability support workers in Australia. Policy and Society, 2023, 42, 104-116.	2.9	2
1467	Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). Pathogens, 2023, 12, 154.	1.2	14
1468	Waning of humoral immunity depending on the types of COVID-19 vaccine. Infectious Diseases, 2023, 55, 216-220.	1.4	5
1469	No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100049.	1.0	0
1470	Deep vein thrombosis during vaccination against SARS-CoV-2 period. Angiologia, 2023, , .	0.0	0
1471	COVID-19 Vaccines—All You Want to Know. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 143-172.	0.8	4
1472	COVID-19 vaccines adverse events: potential molecular mechanisms. Immunologic Research, 2023, 71, 356-372.	1.3	18

#	Article	IF	Citations
1473	Examination of Preferences for COVID-19 Vaccines in Hungary Based on Their Properties—Examining the Impact of Pandemic Awareness with a Hybrid Choice Approach. International Journal of	1.2	0
1474	Environmental Research and Public Health, 2023, 20, 1270. From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era. Biomedicine and Pharmacotherapy, 2023, 158, 114208.	2.5	9
1475	Relevance for mRNA Vaccine Safety. , 2023, , 41-85.		0
1476	Trombosis de eje porto-espleno-mesentérico por sÃndrome de trombosis con trombocitopenia inducida por la vacuna COVID-19 AstraZeneca ChAdOx1nCov-19: reporte de caso. , 2022, 26, .		0
1477	Bystander effect of SARS-CoV-2 spike protein on human monocytic THP-1 cell activation and initiation of prothrombogenic stimulus representing severe COVID-19. Journal of Inflammation, 2022, 19, .	1.5	4
1479	Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety. Vaccines, 2023, 11, 93.	2.1	0
1480	Deep Vein Thrombosis after COVID-19 mRNA Vaccination in a Young Man with Inferior Vena Cava Anomaly Leading to Recurrent Deep Vein Thrombosis. Vascular Specialist International, 0, 38, .	0.2	1
1481	One-year cardiovascular outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry. PLoS ONE, 2022, 17, e0279333.	1.1	11
1482	Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder. International Journal of Hematology, 2023, 117, 341-348.	0.7	3
1483	Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100009.	1.0	3
1484	Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia. Seminars in Thrombosis and Hemostasis, 2023, 49, 444-452.	1.5	6
1485	Vaccine-induced immune thrombotic thrombocytopenia. Blood, 2023, 141, 1659-1665.	0.6	24
1486	The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study. Viruses, 2023, 15, 326.	1.5	1
1487	Variation of the COVID-19 characteristics between genders. , 2023, , 577-593.		0
1488	Cohort event monitoring for safety signal detection in adult individuals 18 years and above after immunisation with coronavirus disease 2019 vaccines in Nigeria. Nigerian postgraduate medical journal, The, 2023, 30, 18.	0.1	0
1489	Extensive Arterial and Venous Thrombosis in a Female With a Known Untreated Polycystic Ovarian Syndrome: A Case Report. Cureus, 2023, , .	0.2	1
1490	Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19. , 2023, , 351-368.		0
1491	Progress in pathophysiological understanding and treatment of thrombocytopenia. International Journal of Hematology, 0, , .	0.7	0

#	Article	IF	CITATIONS
1492	Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity. Frontiers in Immunology, 0, 14, .	2.2	3
1493	Side effects of the COVID-19 vaccines. , 2023, , 711-746.		0
1494	Reactogenicity of various COVID-19 vaccination regimens. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 21, 3476.	0.4	1
1495	Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 2023, 14, .	2.7	4
1496	Cerebral venous sinus thrombosis after COVID-19 vaccination: a case report and literature review. Oxford Medical Case Reports, 2023, 2023, .	0.2	4
1497	Dysregulated platelet function in COVID-19 patients. Obstetrics, Gynecology and Reproduction, 2023, 16, 692-705.	0.2	2
1498	Vaccines: An overview. , 2023, , 699-717.		1
1499	Thrombotic outcomes in patients in a large clinical enterprise following COVID-19 vaccination. Journal of Thrombosis and Thrombolysis, 0, , .	1.0	1
1500	Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?. Vaccines, 2023, 11, 208.	2.1	5
1501	Cerebral Venous Sinus Thrombosis and Papilledema in Vaccine-Induced Thrombotic Thrombocytopenia After SARS-CoV-2 Vaccination. Journal of Neuro-Ophthalmology, 2023, 43, e16-e18.	0.4	2
1502	Superior mesenteric artery thrombosis after the messenger <scp>RNA</scp> â€1273 vaccine. International Journal of Rheumatic Diseases, 2023, 26, 803-804.	0.9	1
1503	Development of High-Grade Sarcoma After Second Dose of Moderna Vaccine. Cureus, 2023, , .	0.2	2
1504	Decreased breadth of the antibody response to the spike protein of SARS-CoV-2 after repeated vaccination. Frontiers in Immunology, 0, 14, .	2.2	1
1505	Acute Uveitis Following AstraZeneca COVID-19 Vaccination. Ocular Immunology and Inflammation, 0, , 1-4.	1.0	2
1508	SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100002.	1.0	0
1510	Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial. Vaccines, 2023, 11, 326.	2.1	4
1511	Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. Chinese Medical Journal, 2023, 136, 24-33.	0.9	2
1512	From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children. International Journal of Molecular Sciences, 2023, 24, 3001.	1.8	12

	CITATION REPORT	
ARTICLE A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutraliz	١F	CITATIONS
antibodies, but not memory T cells, than the homologous BNT162b2 regimen. Vaccine, 2023, 41, 1694-1702.	1.7	5
An analysis of fatal adverse conditions in temporal association of COVID-19 vaccination to boost th safety of vaccination for COVID-19. The Egyptian Journal of Internal Medicine, 2023, 35, .	ne 0.3	1
Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study. Cardiovascular Research, 2023, 119, 1352-1360.	1.8	2
Cerebral Venous Sinus Thrombosis Following an mRNA COVID-19 Vaccination and Recent Oral Contraceptive Use. Life, 2023, 13, 464.	1.1	0
Cardiovascular complications of COVID-19 vaccines: A review of case-report and case-series studies Heart and Lung: Journal of Acute and Critical Care, 2023, 59, 173-180.	S. 0.8	9
Humoral immunity and thrombosis in COVID-19. , 2023, , 375-392.		0
Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mous model. Journal of Genetic Engineering and Biotechnology, 2023, 21, 16.	se 1.5	0
Decompressive surgery in cerebral venous sinus thrombosis due to vaccineâ€induced immune thrombotic thrombocytopenia. European Journal of Neurology, 2023, 30, 1335-1345.	1.7	2
Profiling Humoral Immunity After Mixing and Matching COVID-19 Vaccines Using SARS-CoV-2 Varia Protein Microarrays. Molecular and Cellular Proteomics, 2023, 22, 100507.	ant 2.5	4
Impact of COVID-19 on Cardiovascular Disease. Viruses, 2023, 15, 508.	1.5	15
Investigation of Neurological Complications after COVID-19 Vaccination: Report of the Clinical Scenarios and Review of the Literature. Vaccines, 2023, 11, 425.	2.1	4
Early vs Deferred Non–Messenger RNA COVID-19 Vaccination Among Chinese Patients With a Hi Inactive Uveitis. JAMA Network Open, 2023, 6, e2255804.	istory of 2.8	2
Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 2023, 11, 432.	2.1	17
Platelet Activation and Cytokine Release of Interleukin-8 and Interferon-Gamma-Induced Protein 10 after ChAdOx1 nCoV-19 Coronavirus Vaccine Injection. Vaccines, 2023, 11, 456.) 2.1	1
A systems immunology study comparing innate and adaptive immune responses in adults to COVII mRNA and adenovirus vectored vaccines. Cell Reports Medicine, 2023, 4, 100971.	D-19 3.3	4
Review on COVID-19 Vaccines. Research Journal of Pharmacy and Technology, 2022, , 5868-5874.	0.2	0
Acute pulmonary thromboembolism after messenger RNA vaccination against coronavirus disease 2019: A case report. Journal of Cardiology Cases, 2023, , .	0.2	2

1532	Risk of retinal vein occlusion following COVID-19 vaccination: a self-controlled case series. Eye, 2023, 37, 3000-3003.	1.1	1
------	---	-----	---

#

#	Article	IF	CITATIONS
1533	Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers. Viruses, 2023, 15, 619.	1.5	1
1534	Incidence of sinus thrombosis with thrombocytopenia—A nation-wide register study. PLoS ONE, 2023, 18, e0282226.	1.1	3
1535	Upper extremity deep venous thrombosis after BNT162b2 mRNA COVIDâ€19 vaccine case report. Clinical Case Reports (discontinued), 2023, 11, .	0.2	1
1536	New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF. Frontiers in Immunology, 0, 14, .	2.2	7
1537	SARS-CoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis. Cell Communication and Signaling, 2023, 21, .	2.7	4
1538	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and) Tj ETQq1	1.0.7843 0.8	14 rgBT /O
1539	Real-world data on the incidence and risk of Guillain–Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study. Scientific Reports, 2023, 13, .	1.6	7
1540	Distinct platelet crosstalk with adaptive and innate immuneÂcells after adenoviral and mRNA vaccination against SARS-CoV-2. Journal of Thrombosis and Haemostasis, 2023, 21, 1636-1649.	1.9	6
1541	Cerebral Venous Thrombosis (CVT) Following COVID-19 Vaccination: an Umbrella Review of Systematic Reviews. Iranian Journal of Medical Microbiology, 2023, 17, 7-21.	0.1	0
1542	Circulating SARS-CoV-2+ megakaryocytes are associated with severe viral infection in COVID-19. Blood Advances, 2023, 7, 4200-4214.	2.5	7
1543	The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination. International Journal of Molecular Sciences, 2023, 24, 5644.	1.8	4
1544	End-Stage Kidney Disease Resulting from Atypical Hemolytic Uremic Syndrome after Receiving AstraZeneca SARS-CoV-2 Vaccine: A Case Report. Vaccines, 2023, 11, 679.	2.1	5
1545	The top 100 most cited articles on COVID-19 vaccine: a bibliometric analysis. Clinical and Experimental Medicine, 2023, 23, 2287-2299.	1.9	1
1546	Longitudinal Profiles of Anti-Platelet Factor 4 Antibodies in Thai People Who Received ChAdOx1 nCoV-19 Vaccination. Vaccines, 2023, 11, 692.	2.1	3
1547	Developing an assay to distinguish between HIT and VITT antibodies. Hamostaseologie, 2023, , .	0.9	0
1548	Short-term Side Effects of COVID-19 Vaccines (Astrazeneca, Sputnik-V, and Sinopharm) in Health Care Workers: A Cross-Sectional Study in Iran. Medical Journal of the Islamic Republic of Iran, 0, , .	0.9	0
1549	COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations. , 2023, 14, 2071.		4
1550	Purposing plant-derived exosomes-like nanovesicles for drug delivery: patents and literature review. Expert Opinion on Therapeutic Patents, 2023, 33, 89-100.	2.4	8

#	Article	IF	CITATIONS
1551	Characterising the treatment of thromboembolic events after COVID-19 vaccination in 4 European countries and the US: An international network cohort study. Frontiers in Pharmacology, 0, 14, .	1.6	2
1552	An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?. Canadian Journal of Cardiology, 2023, 39, 865-874.	0.8	2
1553	COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunologic Research, 2023, 71, 537-546.	1.3	10
1554	Never too soon to be thinking about heparin-induced thrombocytopenia! A case report of early onset heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis, 0, Publish Ahead of Print, .	0.5	1
1555	Being Bayesian in the 2020s: opportunities and challenges in the practice of modern applied Bayesian statistics. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2023, 381, .	1.6	2
1556	Kidney Transplantation from a Deceased Donor with COVID-19 Ad26.COV2-S Vaccine-Induced Thrombotic Thrombocytopenia. American Journal of Case Reports, 0, 24, .	0.3	1
1557	Safety of SARS-CoV-2 Vaccination in Patients with Vascular Malformations: Patient-Reported Adverse Vaccine Reactions. Annals of Vascular Diseases, 2023, , .	0.2	0
1558	D-dimer testing: A narrative review. Advances in Clinical Chemistry, 2023, , 151-223.	1.8	1
1559	Post COVID-19 Vaccine-associated Complications. , 2023, 1, .		0
1560	Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study). , 2023, 2, e000302.		2
1561	SARS-CoV-2 RBD and Its Variants Can Induce Platelet Activation and Clearance: Implications for Antibody Therapy and Vaccinations against COVID-19. Research, 2023, 6, .	2.8	3
1562	Patent Foramen Ovale-associated Stroke and COVID-19 Vaccination. Interventional Cardiology Review, 0, 18, .	0.7	1
1563	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis, 2023, 38, 77-278.	0.7	81
1564	Autoantibody-negative but probable pediatric autoimmune encephalitis following COVID-19 vaccination: A case report. Neuroimmunology Reports, 2023, 3, 100173.	0.2	2
1565	Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. EClinicalMedicine, 2023, 58, 101932.	3.2	4
1566	Signal detection of <scp>COVID</scp> â€19 vaccines adverse events using spontaneous reports from South Korea. Pharmacoepidemiology and Drug Safety, 0, , .	0.9	0
1567	Ischemic colitis after receipt of COVID-19 vaccine: Causative or coincidence?. , 2023, , .		0
1568	Thrombotic and Thromboembolic Complications After Vaccination Against COVID-19: A Systematic Review. Cureus, 2023, , .	0.2	0

#	Article	IF	CITATIONS
1569	Safety of COVID-19 vaccines. European Journal of Internal Medicine, 2023, 112, 15-16.	1.0	0
1570	Cartilage-targeting mRNA-lipid nanoparticles rescue perifocal apoptotic chondrocytes for integrative cartilage repair. Chemical Engineering Journal, 2023, 465, 142841.	6.6	3
1571	Diagnosis and Treatment of Cerebral Venous Thrombosis. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 519-539.	0.4	1
1572	<i>Cerebral venous sinus thrombosis following</i> ChAdOx1 nCoV-19 AstraZeneca COVID-19 vaccine. JRSM Cardiovascular Disease, 2023, 12, 204800402311694.	0.4	2
1573	A novel Rift Valley fever vaccine. Lancet Infectious Diseases, The, 2023, , .	4.6	0
1574	Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern. Frontiers in Immunology, 0, 14, .	2.2	3
1575	COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint. Lancet Respiratory Medicine,the, 2023, 11, 395-396.	5.2	2
1576	Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines. Vaccine, 2023, 41, 3422-3428.	1.7	3
1577	Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem. Vaccine, 2023, 41, 3285-3291.	1.7	3
1579	Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®. Vaccines, 2023, 11, 874.	2.1	2
1580	á» NG Dá» 🎙 G XÉT NGHIá» † M HPIA Äá», PHÃT HIá» † N KHÃNG THá», KHÃNG YẾU TổTIá», U CẦU 4 á» ž Bá COVID 19. , 0, , .	»†NH NHÃ	"N _o sau tiãš
1581	á» NG Dá» ĦG XÉT NGHIá» † M HPIA Äá», PHÃT HIá» † N KHÃNG THá», KHÃNG YẾU TổTIá», U CẦU 4 á» ž Bá COVID 19. , 0, , .	»†NH NHÃ	"N _O SAU TIÊ
1584	Serotonin Release Assay: Functional Assay for Heparin- and Vaccine-Induced (Immune) Thrombotic Thrombocytopenia. Methods in Molecular Biology, 2023, , 463-477.	0.4	0
1587	Whole Blood Procoagulant Platelet Flow Cytometry Protocol for Heparin-Induced Thrombocytopenia (HIT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Testing. Methods in Molecular Biology, 2023, , 441-461.	0.4	1
1593	Multiple Electrode Aggregometry (Multiplate): Functional Assay for Vaccine-Induced (Immune) Thrombotic Thrombocytopenia (VITT). Methods in Molecular Biology, 2023, , 429-440.	0.4	0
1640	Covid-19 (Infektion mit SARS-CoV-2). , 2023, , 519-531.		0
1644	Immunization in Europe. , 2023, , 1523-1559.e3.		0
1645	Coronavirus Vaccines. , 2023, , 248-257.e4.		0

IF ARTICLE CITATIONS Vaccine Safety., 2023, , 1679-1695.e10. 1646 0 Neurological symptoms after COVID-19 vaccination: a report on the clinical presentation of the first 50 patients. Journal of Neurology, 2023, 270, 4673-4677. 1649 1.8 Sex-Differential and Non-specific Effects of Vaccines Over the Life Course. Current Topics in 1672 0.7 0 Microbiology and Immunology, 2023, , 225-251. Effects of Biological Sex and Pregnancy on SARS-CoV-2 Pathogenesis and Vaccine Outcomes. Current Topics in Microbiology and Immunology, 2023, , 75-110. Data Mining Strategy to Prevent Adverse Drug Events: The Cases of Rosiglitazone and COVID-19 1674 2.0 0 Vaccines. Artificial Intelligence, 0, , . B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158. 1708 Cerebral Veins and Dural Sinuses Thrombosis: State-of-the-Art Diagnosis., 0,,. 0 Autopsy and COVID-19., 2023, , 677-693. COVID-19 vaccine–induced immune thrombotic thrombocytopenia: pathophysiology and diagnosis. 1734 0.8 0 Annals of Hematology, 0, , . Pharmacotherapeutics for cytokine storm in COVID-19., 2024, , 101-125. 1741

CITATION REPORT